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THREE ESSAYS ON ANALYTICAL MODELS TO IMPROVE EARLY
DETECTION OF CANCER
Chaitra Gopalappa
ABSTRACT
Development of approaches for early detection of cancer requires a comprehensive
understanding of the cellular functions that lead to cancer, as well as implementing
strategies for population-wide early detection. Cell functions are supported by proteins that are produced by active or expressed genes. Identifying cancer biomarkers,
i.e., the genes that are expressed and the corresponding proteins present only in a
cancer state of the cell, can lead to its use for early detection of cancer and for developing drugs. There are approximately 30,000 genes in the human genome producing
over 500,000 proteins, thereby posing significant analytical challenges in linking specific genes to proteins and subsequently to cancer. Along with developing diagnostic
strategies, effective population-wide implementation of these strategies is dependent
on the behavior and interaction between entities that comprise the cancer care system, like patients, physicians, and insurance policies. Hence, obtaining effective early
cancer detection requires developing models for a systemic study of cancer care.
In this research, we develop models to address some of the analytical challenges in
three distinct areas of early cancer detection, namely proteomics, genomics, and disease progression. The specific research topics (and models) are: 1) identification and
quantification of proteins for obtaining biomarkers for early cancer detection (mixed
integer-nonlinear programming (MINLP) and wavelet-based model), 2) denoising of
viii

gene values for use in identification of biomarkers (wavelet-based multiresolution denoising algorithm), and 3) estimation of disease progression time of colorectal cancer
for developing early cancer intervention strategies (computational probability model
and an agent-based simulation).
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CHAPTER 1
INTRODUCTION

Cancer is a result of abnormal behavior of cells with characteristics including uncontrolled growth of cells, and over time, invasion to adjacent tissues and sometimes
metastasizing to different locations of the body via the lymph or blood. Due to this
timeline of cancer, early detection and intervention is crucial. Achieving early detection involves developing diagnostic tools which requires a comprehensive understanding of the cellular functions that lead to cancer (cellular level), and also strategies
for effective population-wide implementation of the developed tools (strategic level).
Before looking into the cause of cancer and the need for analytical models to improve
early detection, it is interesting to look into the evolution of our knowledge of cancer
over the centuries.

1.1

Evolution of Cancer Research
The American Cancer Society in its recent article ([4]) has compiled several inter-

esting facts of the history of cancer over the past centuries, like the earliest scientific
cancer research, evolution of theories for the cause of cancer, and availability of treatment and survival. It has been noted that, the earliest known description of cancer
(the word cancer was not used and was coined only around 300 B.C by Hippocrates)
was in 1600 B.C in an Egyptian textbook on trauma surgery, where it was described
as a disease with no treatment. Since then, there has been tremendous amount of
research and treatment advances, and as of now, the article reports that more than
1

2 out of 3 people diagnosed with cancer survive at least 5 years. However, early
detection is crucial for improved chances of survival as can be seen by the survival
rates per stage of diagnosis in Figure 1.1, which is a summary of the 1996-2006 cancer
statistics reported by the National Cancer Institute’s SEER (Surveillance, Epidemiology and End Results) Program ([5]). The Figure plots the 5-year relative survival
for different primary sites of cancer, and as can be seen for all these sites, survival
when diagnosed at late stage of cancer (distant) is much lower compared to early
stage (local). Therefore, developing tools for early detection of cancer is essential.

Figure 1.1. Five-year relative survival (in %) for different primary sites of cancer

As in any disease, developing diagnosis tools for early detection and further developing effective treatments require an in-depth understanding of the cause of cancer.
It is interesting to present here some of the theories for the cause of cancer with the
evolution of knowledge over the centuries [4]. In 300 B.C. we had the humoral theory,
where it was believed that cancer was caused by excess black bile, one of the four
fluids or humor (blood, phlegm, yellow bile, and black bile) that were required to be
in balance for a person to be healthy. In the late 1700’s we had the lymph theory,
where it was believed that cancer was composed of fermenting lymph fluid. In 1838 it
was realized that cancer was made of cells and not fluid, however, it was not know at
the time that it was the normal cells that become cancerous (blastema theory). Until
1920s some believed that cancer was caused by trauma. It is interesting to point out
2

here that the earliest mention of cancer in 1600 B.C was in a trauma surgery book.
It was only after the mid 20th century with the discovery of the chemical structure
of DNA do we know cancer as of today, as being caused by mutated genes. Without
overlooking the foundation of knowledge laid by past research, though there has been
thousands of years of work in this area, so much of what we know of cancer today
is based on recent advancements, and as stated by the American Cancer Society in
[4] “Scientists have learned more about cancer in the last 2 decades than has been
learned in all the centuries preceding”. It is interesting to point the evolution of our
knowledge from: a balance of four fluids would keep us healthy, to: it is a coordinated
effort of several cell components, like 30,000 genes, and 500,000 proteins; thus, the
vastness of data creating the need for analytical models.

1.2

Brief Description of Cell and Cause of Cancer
The cell is a functional unit of all organisms, and the nucleus of the cell contains

genetic information in the form of DNA. The DNA is considered to be a blue print
that provides instructions for all cellular functions. Cell cycle is a sequence consisting
of DNA replication, growth, and division of cells to form two new cells. Thus the
genetic information is carried from cell to cell.

1.2.1

Chromosomes, DNA, Genes, and Proteins

Humans cells have 23 pairs of chromosomes where each parent contributes one to
each pair. Chromosome is a very long DNA molecule that carry portions of hereditary
information. Genes are sections of DNA that carry on the chromosomes that determine specific human characteristics. The human genome consists of around 30,000
genes, with different genes active or expressed in different parts of the body. Active
genes produce or translate proteins, and more than 500,000 proteins are translated by
3

the human genome. These proteins are the main components that drive the metabolic
activities in a cell which lead to functioning of the different parts of the body. Cancer
is a result of the dysfunction in cellular level metabolic activities

1.2.2

Cancer Biomarkers

Identification of the gene or protein biomarkers of cancer, i.e., the specific genes
that are expressed or the proteins that are present only in cancerous cells, could lead
to its use as cancer diagnostic tools and further drug discovery. Identifying biomarkers
of the earliest stage of cancer can lead to its use as a screening tool for early detection
of cancer. Since response to treatment varies across individuals even for the same
type of cancer, identifying biomarkers could also allow for a more individualized
treatment approach. For example, it is possible that different sets of proteins could
cause the same type of cancer, thereby, identifying behavior of drugs on these protein
sets could lead to a more targeted treatment. It may be noted that engineering
personalized rather than standardized medicines has been identified under one of the
Grand Challenges for the 21st century - Engineering Better Medicine, that was laid
out by the National Academy of Engineering, thus signifying the identification of
cancer biomarkers.

1.3

Need for Analytical Models in Achieving Early Cancer Detection
As is clear from the data in Figure 1.1, early detection of cancer is essential

for improved chances of survival. Advancements in technology, biochemistry, and
medicine has increased our knowledge of the cause of cancer. However, utilizing this
knowledge to develop tools and achieve effective early detection is faced with several
challenges both biochemical and analytical, two of which can be broadly classified as
follows.
4

1. Challenges in identification of gene and protein biomarkers (cellular level):
The vastness of data and complexity of the cell creates analytical hurdles in
biomarker discovery. As an example, we consider the challenges faced in the
general procedure in extracting biomakers. The procedure includes translating
chemical presence of cell components (e.g., genes and proteins in cell samples) to
numerical signals, processing signals to extract meaningful data (e.g., gene expression, or amount of protein), and processing data to extract cancer biomarkers. Some of the challenges include irreproducibility of sample, which arises
due to factors like the same genes producing different proteins under different
conditions of the cell, or proteins changing after production thus resulting in
proteins with different metabolic activities. Each time the sample is converted
to numerical signal, the vastness of data makes it infeasible to manually identify
the values of the cell components, like all genes that are expressed and its level of
expression. Therefore, analytical models need to be developed to automatically
identify the type and amount of the components present in a sample.
2. Effective population-wide implementation of early detection strategies (strategic level): Achieving effective population-wide early cancer detection extends
beyond discovery of cancer screening tools. Utilizing the advances in screening tools requires development of effective screening strategies and moreover its
implementation at a systemic level, i.e, in the general population. The system is comprised of independent decision making entities like the population,
physicians, and insurance policies. Each entity has its own goals that could
sometime conflict with that of the others, and hence, achieving early cancer detection is subject to the behavior and interaction between these system entities.
Therefore, developing effective population-wide early cancer detection strate-

5

gies requires building a model of the entire cancer care system, using which,
implementation strategies can be developed and analyzed.

1.3.1

Research Topics Addressed in this Dissertation

As part of this dissertation, we developed mathematical models to address analytical challenges in the areas of disease progression (strategic level), genomics, and
proteomics (cellular level). The remaining part of this chapter provides a brief description of the specific research topics of this dissertation, and Chapters 2, 3, and 4,
will cover each of these topics in depth.
1. Probability model for estimating disease progression of colorectal cancer: Per
American Cancer Society, colorectal cancer (CRC) is the third most common
cause of cancer related deaths in the United States. Experts estimate that
about 85% of CRCs begin as precancerous polyps, early detection and treatment of which can significantly reduce the risk of CRC. Hence, it is imperative
to develop population-wide intervention strategies for early detection of polyps.
Development of such strategies requires precise values of the population-specific
rates of incidence of polyp and its progression to cancerous stage. There has
been a considerable amount of research in recent years on developing screening based CRC intervention strategies. However, these are not supported by
population-specific estimates of progression rates. This research addresses this
need by developing a probability model that estimates polyp progression rates
considering race and family history of CRC; note that, it is ethically infeasible
to obtain polyp progression rates through case studies. We use the estimated
rates to simulate the progression of polyps in the population of the State of
Indiana. The simulation also includes the screening procedure constructed as

6

per the current screening guidelines for colorectal cancer, and the screening
compliance by the population of Indiana.
2. Mathematical model to remove noise from gene data generated by microarrays: Microarray technology for measuring gene expression values has created
significant opportunities for advances in disease diagnosis and treatment planning. However, random noise introduced by the sample preparation, hybridization, and scanning stages of microarray processing creates inaccuracy in the
estimates of gene expression levels. Literature presents several methodologies
for noise reduction, which can be broadly categorized as: 1) model based approaches for estimation and removal of hybridization noise, 2) approaches using
commonly available image denoising tools, and 3) approaches involving control
samples. In this research we present a novel methodology for identifying and removing hybridization and scanning noise from microarray images, using a dual
tree complex wavelet transform based multiresolution analysis coupled with bivariate shrinkage thresholding. The key features of our methodology include
consideration of specific characteristics of microarray images and the noise distribution, and the ability to work with a single microarray without needing a
control. Our methodology is first benchmarked on a fabricated data set that
mimics a real microarray probe data set. Thereafter, our methodology is tested
on data sets obtained from a number of Affymetrix GeneChip human genome
HG-U133 Plus 2.0 arrays processed on HCT-116 cell line. The results indicate
an appreciable improvement in the quality of the microarray data.
3. Analytical processing of data for estimating protein values: Identification of protein biomarkers in blood and urine samples can provide a non-invasive screening
tool for early detection of cancer. Developing such screening tools requires iden7

tifying all the proteins that are produced in the body and further identifying
those that distinguish cancer cases from controls. Due to the large number of
proteins produced by the human body ( 500,000), most of which are present in
small amounts in blood and urine, the biochemical processing of the blood or
urine samples need to be accompanied by automatic mathematical algorithms
that identify and quantify the proteins. Developing such mathematical algorithms is a challenging task due to vastness of data which is further complicated
by the complex biochemical nature of the problem. In this research, we develop
wavelet and optimization algorithms for analytical processing of the data to
obtain protein information across several samples, using which, biomarkers can
be identified.

8

CHAPTER 2
MODEL FOR COLORECTAL POLYP PROGRESSION

2.1

Introduction
Colorectal cancer (CRC) is the third most common cause of cancer related deaths

in the U.S. Most CRCs begin as precancerous polyp ([6, 7]), referred to as adenomacarcinoma sequence ([8]). Employing effective population-wide strategies for early
detection and treatment at precancerous stages can lead to significant reduction in
CRC mortalities. Literature presents a considerable amount of research on developing CRC screening strategies with varying tests and time lines, and examining
their influence on mortality rates. However, developing feasible intervention strategies requires a system-based model of cancer care that must consider, in addition to
screening alternatives, various other interacting elements of the system, including the
social-behavioral traits of the people and the physicians, and the parameters of the
insurance policies. Two important processes of the system-based cancer care model
are: polyp incidence and polyp progression. Polyps follow a natural incidence and
progression, and upon diagnosis, drive the behavior and interaction of the system elements. Thus, precise models portraying the incidence and the progression processes
are fundamental to developing effective intervention strategies. In this research, our
attention is focused on developing a probability model to estimate progression rates
of colorectal polyps.

9

The literature contains a considerable number of simulation and mathematical
models for CRC screening strategies ([9, 10, 11, 12, 13, 14, 15, 1, 16], and CISNET
models [17]). All of these cited works have a natural history component for the
incidence and progression of polyps, most of which are modeled using variants of
Markovian techniques. The main inputs required for these Markovian models are the
incidence rates of polyps, and progression rates between stages, e.g., the inverse of the
time that polyps take to progress from adenoma (pre-malignant) to carcinoma. The
incidence rates have been estimated based on case study results involving randomized
screening and follow-up. However, for progression rates, a case study approach is not
feasible, since it is unethical to keep a diagnosed polyp under observation without
treatment. As a result, most of the above models use progression rates that are
derived based on expert opinion, obtained either by convening a panel or by utilizing
the data presented in [18] and [19].
Mathematical models, in contrast to the models based on expert opinion, can
incorporate characteristics like race and family history of CRC, and hence estimate
population-specific progression rates. The National Academy of Engineering, under
one of the Grand Challenges for the 21st century - Engineering Better Medicine,
noted the need for engineering personalized rather than standardized medicines since
“people differ in susceptibility to disease and response to medicine.” Also, progression
rates in the pre-diagnosis phase may vary between populations, thus underscoring the
need for population-specific progression rates. Although literature presents numerous
models and cost based analysis of CRC screening strategies, and numerous models and
case studies on incidence rates, mathematical models to estimate polyp progression
rates have been limited ([20], [21]). The study presented in [20] uses the data from the
national colonoscopy screening database of Germany to develop a statistical approach
to obtain annual transition rate and the 10 year cumulative risk of CRC specific to sex
10

and age groups. The transition rates are only for after the onset of advanced adenoma
(polyp≥1cm). A Markov model to estimate progression rates for stages after the onset
of cancer, and the incidence of cancer is presented in [21]. The model was built based
on the results of a case study conducted on a population with high-risk of CRC.
In this research, we present a probability model that was developed for estimating
polyp progression rates, specific to race and family history status, from the incidence
of polyp to carcinoma and between stages of carcinoma. Note that, estimating progression rates, and thus time to progress, from incidence of polyp to carcinoma are of
vital importance for developing early pre-cancer intervention strategies. The polyp
progression pathways considered in our model are depicted in Figure 2.1 and are
described as follows.
CRC Pathways- Polyp incidence and stages of progression: Most CRCs originate
as visible precancerous polyps and only a small percentage arise as flat carcinoma. Not
all polyps are pre-malignant and hence only some progress to carcinoma. While CRCs
generally develop from polyps greater than 1cm, carcinoma has also been diagnosed
in polyps between 6mm and 9mm ([19]). In this research, we consider three possible
pathways for polyp progression before the onset of cancer. Figure 2.1 depicts the three
pathways and the four stages of colorectal cancer. Polyp-pathways 1 and 2 refer to
the progression types that begin with a visible adenoma polyp before progressing to
cancer; this was adopted from the pathways presented by [19]. Non-polyp pathway
refers to the cancers arising from flat polyps ([22]). After the in-situ stage, the polyp
progresses through the three stages of invasive cancer: local, regional, and distant,
which when related to Dukes classification of cancer ([23]), correspond to stages A+B,
C, and D, respectively. Note that, while most cancers begin as pre-cancerous polyp,
not all polyps progress to cancer, i.e, remain in the benign stages. Hence, polyps
can be categorized into progressive and non-progressive ([19]). In what follows, we
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present our probability model, results estimated from the probability model, the
model validation, and concluding remarks.

Figure 2.1. CRC pathways: Polyp incidence and stages of progression

2.2

Probability Model to Estimate Progression Rates
One of the main inputs required to develop the progression rate model is the inci-

dence rate of polyps specific to patient’s age, race, and family history status of CRC.
In this section, we first present our method for estimating incidence rates, followed
by the development of a probability model for estimating progression rates. The
probability model was developed based on the assumption that non-polyp pathway
contributes towards 15% of cancers, and 70% of cancers from the polyp pathways
arise from pathway 1 (based on expert opinions cited in [19] and [11]). All notation
used in the model presented in this section are summarized in Table 2.1.

2.2.1

Polyp Incidence Rates

We estimated the probability of incidence of polyp≤5mm, which is the first visible
stage on the polyp pathways, by utilizing the case studies presented in [24] and
12

Table 2.1. Notation used in the probability model
Symbol
p5 , S, L, R, D
p5t , St , Lt , Rt , Dt
S̃ t , L̃t , R̃t , D̃t
C˜t
ĨC t
F
R
At
L
Z+
NS
NL
ND
Tij
λji|rf

Description
events of incidence of polyp≤5mm, in-situ CRC, local CRC, regional CRC, distant CRC
p5 , S, L, R, and D at time t
events of prevalence of in-situ CRC, local CRC, regional CRC, and distant CRC, at time t
event of prevalence of CRC (in-situ, local, regional, or distant), at time t
event of prevalence of invasive CRC (local, regional, or distant), at time t
random variable denoting family history of CRC of a randomly selected individual
random variable denoting race of a randomly selected individual
random variable denoting age (in years) of an individual at time t
random variable denoting length of life in years
set of positive integers
number of stages from p5 to S
number of stages from S to L
number of stages from initial event (p5 or S) to distant CRC (D)
time to progress from event i to j
progression rate from event i to event j given R = r and F = f

[25]. The study in [24] presents data on the number of positive sigmoidoscopy results
(indicating polyps) in a population that had tested negative (indicating normal) three
years back. Using this repeated test data, we estimated the probability of incidence of
polyp≤5mm per year. Studies have shown that the rate of polyp incidence varies with
age, however, [24] did not contain enough data to estimate the incidence probabilities
based on age groups. Therefore, we used the statistics in [25], which presents agebased data of patients undergoing polyp detection and removal at the Rochester
Methodist Hospital, Rochester, Minnesota. It has also been observed in the literature
that a family history of CRC increases the risk of developing CRC ([26] and [25]).
Therefore, we considered population specific incidence rates, which we estimated as
follows.
Let p5t1 denote an event of incidence of polyp≤5mm at time t1 , and At1 ∈ Z +
be the random variable denoting the age at t1 , where Z + denotes the set of positive
integers. Let R and F be the random variables denoting the race and the status of
family history of CRC, respectively, of a randomly selected individual. We consider
R = {Caucasian, Af rican American, Other}, and F = {0, > 0}, i.e., F has 2
outcomes, either no family history of CRC (event F = 0) or atleast one case of CRC
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in the family (event F > 0). We computed the joint probabilities of p5t1 and At1 in
interval [a, b], for given events of F = f and R = r as follows. Let the probability of
p5t1 given R = r and F = f (i.e., P {p5t1 |R = r ∩ F = f }) be denoted by Prf {p5t1 }.
Applying the definition of conditional probability, and since p5t1 and R = r ∩ F = f
are dependent events we can write that

Prf {p5t1 } =

P {p5t1 ∩ R = r ∩ F = f }
,
P {R = r ∩ F = f }

(2.1)

and also since Prf {p5t1 } and a ≤ At1 ≤ b are dependent events we can write that
n

o

n

o

n

o

Prf (a ≤ At1 ≤ b) ∩ p5t1 = Prf (a ≤ At1 ≤ b)|p5t1 Prf p5t1 .

(2.2)

The probability values for the elements on the right hand side of equations (2.1) and
(2.2) are estimated using data from: [24] for probabilities of p5t1 ; [25] for probability
distributions based on At1 and F ; and [27] for probability distributions based on R.
A detailed description of the estimation is presented below.
1. Estimating P {F = f ∩ R = r}: Using the definition of conditional probability,
since F = f and R = r are dependent events, we can write P {F = f ∩R = r} =
P {F = f |R = r}P {R = r}. To compute P {F = f |R = r}, we consider that
the number of CRCs per family (i.e., the family history status F ) is Poisson
distributed with mean µr for a given race. We estimate µr for each race as
{ N umberof CRCcasesinthepopulation(i.e.,CRCprevalencecount)
∗ Averagef amilysize}. The
T otalpopulation
CRC prevalence count for year 2006 for each race was obtained from SEER
(Surveillance Epidemiology and End Results) database ([28]), which presents
CRC statistics of the U.S. population. The total population count in year 2006
for each race was obtained from the U.S. census data. The average family size
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of the U.S. population is 3.20, as reported by census ([29]). With the inclusion
of second degree relatives, we assume that the average family size for all race
is 7. Using the Poisson distribution probability density function, we compute
P {F = f |R = r} =

(µr )f e−µr
,
f!

and P {R = r} can be easily computing using the

U.S. census data. For equation (2.1), we compute P {F = 0 ∩ R = r} as above,
and P {F > 0 ∩ R = r} = (1 − P {F = 0|R = r})P {R = r}. We present below
the estimates of µr and P {F > 0|R = r}100 in Tables 2.2 and 2.3
Table 2.2. Estimates of the Poisson parameter µr
R = All Race R = Caucasian
0.026
0.028

R = African American
0.018

Table 2.3. Percentage of population with family history of CRC given race (P {F >
0|R = r}*100)
R = All Race R = Caucasian
2.55
2.77

R = African American
1.77

n

o

2. Estimating P {p5t1 ∩ R = r ∩ F = f } and Prf (a ≤ At1 ≤ b)|p5t1 : The article
in [24] presents part of the results of a large-scale randomized Prostate, Lung,
Colorectal, and Ovarian Screening Trial (PLCO) [30], that was conducted to
test the effect of various screening tests on mortalities from the cancers. As part
of the colorectal cancer study, initially, a population in the age group 55-74 was
screened for colorectal polyps. On the population that tested negative (indicating normal), a repeated screening test was conducted three years after the
initial screen test. The number of positive (indicating presence of polyp) screen
results from the repeated test has been presented in [24]. The diagnosed polyps
have been categorized into sizes <0.5, 0.5-0.9, and ≥1.0 cm. Since all polyps
should have started as <0.5cm with the event of incidence occurring during
15

one of the three years between tests, we estimate the probability of incidence
of polyp≤5mm at an arbitrary year t1 (P {p5t1 }) as
where, we multiply by

1
3

1
3

∗ N umberofTpeopletestedpositive
,
otaltested

assuming that there were equal number of incidences in

each of the three years. However, note that, age groups 40-54 and >74 were not
part of the study population in [24], and hence, the above estimate of P {p5t1 }
will only apply to population in age 55-74. Therefore, to estimate P {p5t1 } for
the required population (i.e., age>40) we perform simple mathematical calculations using: i) the percentage distribution of polyps across age groups from
[25], and ii) percentage distribution of U.S. population across age groups, taken
from the U.S. census data.
Applying the definition of conditional probability, we compute P {p5t1 ∩ R = r ∩
F = f } = P {(R = r ∩ F = f )|p5t1 }P {p5t1 }. Since, when given event p5t1 , we do
not have data to determine dependence of events F = f and R = r, we assume
independence and compute P {(R = r ∩ F = f )|p5t1 }P {p5t1 } = P {R = r|p5t1 }P {F =
f |p5t1 }P {p5t1 }. We can estimate P {R = r|p5t1 } =

N umberof polypcasesinracer
,
T otalpolypcases

however,

since we did not have suitable data to determine this proportion, we approximated
P {R = r|p5t1 } =

N umberof CRCcasesinracer
,
T otalCRCcases

data for which was obtained from the Indiana

database ([27]). We estimate P {F = 0|p5t1 } =

N umberof polypcaseswithf amilyhistoryof CRC
T otalpolypcases

=

0.14 using data presented in [25], and P {F > 0|p5t1 } = 0.86. Also, Prf {(a ≤ At1 ≤
b)|p5t1 } is equated to the proportion of polyps in respective age groups as presented
in [25].
Note that, we consider the minimum age for developing a polyp as 40 years,
since risk of cancer below 40 is low based on discussions presented in [31] and [32].
The report by the American Cancer Society in [31] notes that 90% of CRCs are
diagnosed in individuals above the age of 50. Also, the expert panel from the U.S.
Multisociety Task Force on Colorectal Cancer suggests a starting screening age of
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50 years and 40 years for individuals without and with a family history of colorectal
polyps, respectively ([32]).

2.2.2

Probability Model to Estimate Progression Rates

Based on expert opinion ([20], [9]), we consider that the progression times for
the following events of incidences: polyp≤5mm to in-situ CRC, in-situ to local CRC,
local to regional CRC, and regional to distant CRC are exponentially distributed
with event dependent parameters (progression rates). It may be noted that accurate estimation of the progression rate from the incidence of pre-cancerous polyp
(polyp≤5mm) to carcinoma (in-situ), is crucial for developing effective pre-cancer
intervention strategies.
Let λji|rf denote the progression rate from event i to event j given R = r and
F = f . In what follows, we present models for estimating λji|rf for pre-cancer event
(from incidence of polyp≤5mm to incidence of in-situ) considering polyp pathways 1
and 2 (see Figure 2.1), and post-cancer events (between incidence of different CRC
stages) considering all pathways.

2.2.2.1

Estimating Pre-Cancer Progression Rate

Pre-cancer progression rate, which we will denote as λSp5 |rf , refers to the inverse of
the expected time to progress from incidence of the first stage of visible polyp ≤5mm
(p5 ) to incidence of in-situ CRC (S), given R = r and F = f .
Note: Not all p5 progress to S. Those that do progress are called progressive polyps
and the rest non-progressive. In this research, the estimation of λSp5 |rf considers cases
of both progressive and non-progressive polyps. In other words, if the random value
for the time to progress to in-situ, selected from the distribution exponential(λSp5 |rf ),
is such that it exceeds the natural life, then the polyp is considered non-progressive.
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We now present the model for estimating λSp5 |rf . Let St2 denote the event of
incidence of in-situ CRC at time t2 . Recollect that p5t1 denotes p5 at time t1 , and
At denotes age at time t, then following polyp pathways in Figure 2.1, t2 > t1 (as
represented in Figure 2.2). For a population with St2 , since events of p5t1 ∩ At1 =
α ∩ At2 = β are mutually exclusive (i.e.,

P P
α

β>α (p5t1

∩ At1 = α ∩ At2 = β) = 1) and

exhaustive, we can apply the total probability rule and write that

Figure 2.2. Event of incidence of polyp≤5mm at time t1 (p5t1 ) and its progression to
an event of incidence in-situ CRC at time t2 (St2 ), with age at t1 and t2 as α and β,
respectively

P (St2 ) =

XX
α β>α

n

o

n

o

P St2 |(p5t1 ∩ At1 = α ∩ At2 = β) P p5t1 ∩ At1 = α ∩ At2 = β .
(2.3)

Let TpS5 be a random variable denoting the time to progress from p5 to S. Referring
o

n

to Figure 2.2, P St2 |(p5t1 ∩ At1 = α ∩ At2 = β) is equivalent to
o

n

P TpS5 = β − α|(p5t1 ∩ At1 = α ∩ At2 = β) , therefore, we can rewrite equation (2.3)
as,

P (St2 ) =

XX

n

o

n

o

P TpS5 = β − α|(p5t1 ∩ At1 = α ∩ At2 = β) P p5t1 ∩ At1 = α ∩ At2 = β .

α β>α

(2.4)

Applying conditional probability, equation (2.4) can be written as,

P (St2 ) =

XX

n

o

P TpS5 = β − α|(p5t1 ∩ At1 = α ∩ At2 = β)

α β>α

n

o

P p5t1 |(At1 = α ∩ At2 = β) P {At1 = α ∩ At2 = β} ,
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(2.5)

n

o

n

o

where, P p5t1 |(At1 = α ∩ At2 = β) can simply be written as P p5t1 |At1 = α , since
incidence of polyp≤5mm at time t1 is only dependent on age at t1 and not on age at
n

o

any future time t2 . Using the estimate from equation (2.2), P p5t1 |At1 = α can be
P {p5t ∩(a≤At1 ≤b)}
1
1
computed as
, a ≤ α ≤ b, i.e., by applying conditional probb−a+1
P (A=α)
ability and assuming constant rate of incidence within each age interval. Note that,
the assumption is in accordance with that in the microsimulation model MISCANcolon, that evaluates CRC screening policies ([9]), and whose input parameter values
were based on expert estimates presented in meetings at the National Cancer Instin

o

tute. Further, in equation (2.5), P (TpS5 = β − α)|(p5t1 ∩ At1 = α ∩ At2 = β) can be
S

substituted as λSp5 e−λp5 (β−α) , where λSp5 denotes progression rate from p5 to S. The
remaining term on the right hand side of (2.5) can be estimated using population
demographics from U.S. census data. Hence, λSp5 can be estimated using (2.5) if the
probability on the left hand side is available. However, P {St2 } is unknown, and is
infeasible to estimate with the currently available data as explained below.
Let us divide the in-situ CRC stage as a series of sequential events {s0 , s1 , s2 , · ·
·, sn }, where si is an event indicating i time units of cancer progression in the insitu stage. To relate S to si , we need to consider smaller time units (e.g., day),
in which case S is equivalent to s0 , denoting the event of epoch of incidence of insitu. Note that, for a diagnosed case of in-situ CRC, it is not possible to determine
the value of i, and hence, we cannot obtain data related to the occurrence of each
event si . Therefore, it is not feasible to estimate P {S}. However, it is possible to
estimate the probability of event of prevalence of in-situ CRC, i.e., P {∪ni=1 si }, as
equal to the proportion of people in stage in-situ CRC in a randomized screening
trial (we will denote P {∪ni=1 si } at an arbitrary time t2 as P {S̃ t2 }). Due to the
unavailability of a suitable randomized study that can be used to estimate P {S̃ t2 },
we estimated P {C˜t2 }, which is the probability of prevalence of CRC at t2 . That is,
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P {C˜t2 } = P {S̃ t2 ∪ L̃t2 ∪ R̃t2 ∪ D̃t2 }, where, the events in the probability term on the
right hand side of the equation denote the prevalences of in-situ CRC, local CRC,
regional CRC, and distant CRC, respectively, at time t2 . Therefore, Figure 2.2 is
modified to include the above changes and is presented as Figure 2.3. As illustrated
by Scenarios 1 through 4 in the Figure, for a randomly chosen individual at t2 , C˜t2
corresponds to an event of prevalence of one of the CRC stages.
To reflect the above changes we modify equation (2.5) as follows,

Figure 2.3. Event of incidence of polyp≤5mm at time t1 (p5t1 ) and its progression to
an event of prevalence of CRC at time t2 (C˜t2 ) (i.e., either S̃ t2 , L̃t2 , R̃t2 , or D̃t2 ), with
age at t1 (At1 ) and t2 (At2 ) as α and β, respectively

P {C˜t2 } =

XX
α β>α

n

o

n

P TpS5 ≤ β − α|(p5t1 ∩ At1 = α ∩ At2 = β) P p5t1 |At1 = α

o

P {At1 = α ∩ At2 = β} (2.6)
where, left hand side has been replaced with P {C˜t2 }. Also, we have TpS5 ≤ β−α instead
of = β − α, since, an occurrence of C˜ at t2 does not necessarily mean occurrence of s0
˜ Also since, S (or s0 ) is the first of the set of chronological events that make
(i.e., s0 C).
˜ age at S is ≤ β implying that T S ≤ β − α. P {C˜t2 } was estimated using data from
C,
p5
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[33], which presents screen results from CRC counseling and screening conducted by
10 health departments in 15 diverse counties in the state of North Carolina, as part
of a pilot study on cancer coordination and control.
Referring to Figure 2.3, the upper bound on TpS5 , i.e., TpS5 = β − α, is represented
by Scenario 1, while a lower bound would be represented by Scenario 4. To quantify
the lower bound, we can consider a value of one year, however, this may not be
realistic and can be explained with the following examples. For a combination of
values for {At1 = α, At2 = β} consider an example of {At1 = 40, At2 = 43}. Referring
to Scenario 4, if TpS5 = 1, it will imply that age at S̃ t2 is 41, and age at D̃t2 is 43,
i.e., it takes 2 years to progress from in-situ to distant CRC. Similarly, if instead,
we consider an example of {At1 = 40, At2 = 70}, if TpS5 = 1, it will imply that age
at S̃ t2 is 41, and age at D̃t2 is 70, i.e., it takes 29 years to progress from in-situ to
distant CRC, while it took only 1 year to progress from polyp≤5mm to in-situ CRC.
This is highly unlikely since the progression between cancer stages is faster compared
to precancer stages. Therefore, in order to place a more realistic lower bound, we
consider equal time to progress between stages, and referring to Scenario 4, we write
TpS5 ≥

(β−α)NS
,
ND

where NS and ND are the number of stages from polyp≤5mm to in-

situ CRC and polyp≤5mm to distant CRC, respectively. As an example, for polyp
pathway 1 in Figure 2.1, NS = 3 and ND = 7. Note that, the equal time between
stages was an assumption made only for obtaining a more realistic lower bound, than
using an arbitrary value of one year, and was not an assumption on the progression
rate estimation.
The modified equation can be written as,
(

P (C˜t2 ) =

XX
α β>α

P

)

NS (β − α)
≤ TpS5 ≤ (β − α)|(p5t1 ∩ At1 = α ∩ At2 = β)
ND
n

P p5t1 |At1 = α}P {At1 = α ∩ At2 = β
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o

(2.7)

where,
(

P

)

NS (β − α)
≤ TpS5 ≤ (β − α)|(p5t1 ∩ At1 = α ∩ At2 = β) =
ND
h

1−e

−λS
p5 (β−α)

i

"

−λS
p5 NS



− 1−e

β−α
ND

#

since the bounds on the progression time is equivalent to the event TpS5 ≤ (β −
α)

T

TpS5 ≥

NS (β−α)
.
ND

Note that, the formulation in equation (2.7) will imply that

every individual with p5 at t1 will live through to time t2 , however in reality this is
not the case. Therefore, denoting L ∈ Z + as a random variable indicating length of
life, we write (2.7) as,
(

P (C˜t2 ) =

XX
α β>α

P

)

NS (β − α)
≤ TpS5 ≤ (β − α)|(p5t1 ∩ At1 = α ∩ At2 = β)
ND
o

n

P p5t1 |At1 = α P {At1 = α ∩ At2 = β} P {L > β}
where,
n

P

NS (β−α)
ND

o

≤ TpS5 ≤ (β − α)|(p5t1 ∩ At1 = α ∩ At2 = β)

h

−λS
p5 (β−α)

= 1−e

i

"

− 1−e

−λS
p5 NS



β−α
ND

#

(2.8)

In equation (2.8), the only unknown value is the progression rate λSp5 which can be
computed by iteratively incrementing its value to where it best fits (2.8). Before doing
so however, in order to obtain population-specific progression rates, we estimate λSp5 |rf ,
which denotes λSp5 given race (R = r) and family history status (F = f ), as follows.
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Since events of R = r ∩ F = f are mutually exclusive (i.e.,

P {R = r ∩ F =

P P
r

f

f } = 1) and exhaustive, applying the total probability rule we can write,

P (C˜t2 ) =

XX
r

n

o

P C˜t2 |(R = r ∩ F = f ) P {R = r ∩ F = f }

f

=

XX
r

n

o

P C˜t2 ∩ R = r ∩ F = f .

(2.9)

f

Note that, equation (2.8) for a given R = r ∩ F = f is equivalent to P {C˜t2 |(R =
r ∩ F = f )} of equation (2.9). Therefore, we can write
n

o

P C˜t2 ∩ R = r ∩ F = f =

XX


(

Prf

α β>α

NS (β − α)
≤ TpS5 ≤ (β − α)|(p5t1 ∩ At1 = α ∩ At2 = β)
ND
n

o

)

i

Prf p5t1 |At1 = α Pr {At1 = α ∩ At2 = β} Pr {L > β}
P {R = r ∩ F = f }

∀r∀f,

(2.10)

where,
Prf

n

NS (β−α)
ND

≤ TpS5 ≤ (β − α)|(p5t1 ∩ At1 = α ∩ At2 = β)


"

= 1−e

− λS
p

5 |rf



(β−α)

#

o
"





− λS
p

5 |rf

− 1−e

NS



β−α
ND

#

.

Note that, occurrences of Prf {(.)} in (2.10) (and henceforth) represent P {(.)|(R =
r ∩ F = f )}, and have been written as such for notational convenience. Applying conditional probability, we can write P {C˜t2 ∩ R = r ∩ F = f } = P {(R =
n

o

r ∩ F = f )|C˜t2 }P C˜t2 . Since not enough data is available to determine the dependence of events F = f and R = r when given C˜t2 , we assume independence and
n

write P C˜t2 ∩ R = r ∩ F = f
n

o

n

o

n

o

n

o

= P R = r|C˜t2 P F = f |C˜t2 P C˜t2 . As men-

o

tioned earlier, P C˜t2 is estimated using data presented in [33]. We compute P {(R =
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r)|C˜t2 } =

N umber of CRC cases in race r
,
T otal number of CRC cases

where the required numbers are obtained from

the Indiana State Department of Health database ([34]). We consider P {(F =
f )|C˜t2 } = 0.2 based on the observations reported by the American Cancer Society in
[35]. Note that, estimates of P {R = r ∩ F = f } were earlier obtained for equation
(2.1), the details of which are described in Section2.2.1. Therefore, the only unknown
element in (2.10) is λSp5 |rf , and hence, can be easily estimated for all values of r and
f.

2.2.2.2

Estimating Post-Cancer Progression Rates

This section discusses the estimation of progression rates between CRC stages,
i.e, between stages in-situ, local, regional, and distant, with events of incidences
denoted as S, L, R, and D, respectively. A similar model as that developed for
estimating λSp5 |rf in equation (2.10) can be used in estimation of the progression rates
between the CRC events. For example, consider event of incidence of in-situ at time
t2 (St2 ) and consider ĨC t3 , the event of prevalence of invasive CRC at time t3 (i.e.,
P {ĨC t3 } = P {L̃t3 ∪ R̃t3 ∪ D̃t3 }), as represented by Figure 2.4. We can estimate the
progression rate from S to L given R = r and F = f , denoted as λLS|rf , by the
following equation
(

Prf {ĨC t3 } =

XX
α β>α

Prf

NL (β − α)
≤ TSL ≤ (β − α)|(St2 ∩ At2 = α ∩ At3 = β)
ND

Prf {St2 |At2 = α} Pr {At2 = α ∩ At3 = β} Pr {L > β}

where,

Prf

n

NS (β−α)
ND

o

≤ TSL ≤ (β − α)|(St2 ∩ At2 = α ∩ At3 = β) =
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)

∀r, ∀f (2.11)

Figure 2.4. Event of incidence of in-situ CRC at time t2 (St2 ) and its progression to
an event of prevalence of invasive CRC at time t3 (ĨC t3 ) (i.e., either L̃t3 , R̃t3 , or D̃t3 ),
with age at t2 (At2 ) and t3 (At3 ) as α and β, respectively


"



− λL
(β−α)
S|rf

1−e

#

"

− 1−e





− λL
NL
S|rf



β−α
ND

#

,

TSL denotes time to progress from S to L, and NL and ND in the lower bound of TSL
now represent the number of stages from S to L and S to D, respectively. Prf {ĨC} at
˜ = Prf {C}P
˜ rf {ĨC|C}.
˜
an arbitrary time t3 can be estimated as Prf {ĨC} = Prf {ĨC ∩ C}
˜ is obtained as earlier from [33], and Prf {ĨC|C}
˜ is obtained using CRC diagPrf {C}
nosed data from the Indiana database [36]. Therefore, from equation (2.11), we
can estimate λLS|rf if the only unknown Prf {St2 |At2 = α} can be computed, since
the rest of the terms can be obtained similar to the equivalent terms in equation
(2.10). However, as explained in Section 2.2.2.1, it is infeasible to estimate P {S}
using results from randomized screening trials, hence it is also not feasible to estimate Prf {St2 |At2 = α} using screening trials. Note however that, at this point in
the model, we have estimated λSp5 |rf , the progression rate from p5 to S. Therefore,
n

o

using the estimated values of Prf p5t1 ∩ (a ≤ At1 ≤ b) from Section 2.2.1 and λSp5 |rf
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from Section 2.2.2.1, we developed a model to estimate Prf {St2 |At2 = α}, which is
explained below.
The schematic of the probability model developed for estimating Prf {St2 |At2 = α}
is presented in Figure 2.5, and can be interpreted as follows. Consider p5 at time
t1 and its progression to S at t2 , t1 < t2 . Now considering age at t1 and t2 , if
c ≤ At2 ≤ d and a ≤ At1 ≤ b, then {∀a, b, c, d : [a, b] ≤ [c, d]}. For example,
considering age intervals [40,49], [50,64], [65,74], and [75,], if At2 = [40, 49] then
At1 = [40, 49], and if At2 = [50, 64] then At1 = [40, 49] or At1 = [50, 64]. Accordingly,
n

o

Prf {St2 ∩ (c ≤ At2 ≤ d)} can be estimated by using Prf p5t1 ∩ (a ≤ At1 ≤ b) and
λSp5 |rf , ∀a, b, c, and d, as follows,

Figure 2.5. Event of incidence of polyp≤5mm at t1 (p5t1 ) and its progression to an
event of incidence of in-situ CRC at t2 (St2 ), with age a ≤ At1 ≤ b and c ≤ At2 ≤ d
such that [a, b] ≤ [c, d]

n

X

Prf {St2 ∩ (c ≤ At2 ≤ d)} =

o

Prf p5t1 ∩ (a ≤ At1 ≤ b)

[a,b]≤[c,d]



b−1
X

d−k
X





Prf {TpS5 = m|(p5t1 ∩ At1 = k)}P {L > m + k}

k=a m=max(k+1,c)−k

(2.12)
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 −m λS
p

where, Prf {TpS5 = m} = λSp5 |rf e



5 |rf

. Note that, equation (2.12) was derived

by a simple application of the total probability rule. For example, considering one
specific age at At2 as 50, we can write Prf {St2 ∩ At2 = 50} =

P

α<50

Prf {St2 ∩ At2 =

50|(p5t1 ∩At1 = α)}Prf {p5t1 ∩At1 = α)} = Prf {TpS5 = 50−α|(p5t1 ∩At1 = α)}Prf {p5t1 ∩
At1 = α)}. Equation (2.12) however has been written for an age interval, and has the
variable L which denotes the length of life of an individual.
Prf {St2 |At2 = α}, required for equation (2.11), can now be estimated from Prf {St2 ∩
(c ≤ At2 ≤ d)} by applying conditional probability, and by considering a constant
rate of incidence within each age interval, which is in accordance to literature as
explained earlier. Equation (2.11) can now be solved to obtain λLS|rf . The progression rates from local to regional CRC and regional to distant CRC can similarly be
estimated by cyclically computing the probability of event of incidence (similar to
computation of Prf {St2 |At2 = α} using equation (2.12)) followed by estimation of the
progression rates (similar to estimation of λLS|rf using equation (2.11)). Note that,
for stages past in-situ, L also includes survival based on stage of cancer in addition
to the natural life of an individual.

2.3

Results: Estimated Incidence and Progression Rates
In Tables 2.4 and 2.5, we present rates of p5 for polyp pathways and rates of S for

non-polyp pathway, respectively, for different combinations of age, race, and family
history status. For example, in Table 2.4, the percentage of incidence of polyp≤5mm
at age 50 ≤ A ≤ 64 and R = Caucasian and F > 0 is 4.25. The mean times to
progress from event i to event j given R = r and F = f , i.e.,

1
,
λji|rf

are presented

in Tables 2.6 and 2.7, for polyp pathways and non-polyp pathway, respectively. The
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values in Tables 2.4 through 2.7 will serve as input for developing a model of polyp
progression. Such a model is essential for developing CRC intervention strategies.
Table 2.4. Prf (p5 ∩ a ≤ A ≤ b)100: Percentage incidence of polyp≤5mm at age [a, b],
given R = r and F = f , for polyp pathways
Age Group [a, b]
[40, 49]
[50, 64]
[65, 74]
[75, ]

All Race
F >0 F =0
0.74
0.12
4.33
0.70
4.54
0.73
2.13
0.34

R = Caucasian
F >0
F =0
0.73
0.13
4.25
0.74
4.46
0.78
2.09
0.36

R = African American
F >0
F =0
0.90
0.10
5.28
0.58
5.53
0.61
2.59
0.29

Table 2.5. Prf (S ∩ a ≤ A ≤ b)100: Percentage incidence of in-situ CRC at age [a, b],
given R = r and F = f , for non-polyp pathway
Age Group [a, b]
[40,49]
[50,64]
[65,74]
[75,]

All Race
F >0 F =0
0.025
0.002
0.257
0.026
0.330
0.034
0.344
0.040

R = Caucasian
F >0
F =0
0.026
0.003
0.265
0.029
0.339
0.038
0.346
0.044

R = African American
F >0
F =0
0.024
0.002
0.252
0.018
0.318
0.023
0.332
0.026

Table 2.6. Mean times to progress from event i to event j, given R = r and F = f
( λj1 ) on polyp pathways
i|rf

event i → event j
p5 → in-situ a
in-situ → local
local → regional
regional → distant
a

: λS
p

5 |rf

2.3.1

All Races
F >0
F =0
23
41.6
3.4
3.4
5
5
0.95
0.95

R = Caucasian
F >0
F =0
21.5
39
3.5
3.5
4.5
4.5
0.95
0.95

R = African American
F >0
F =0
29
50
3.1
3.1
3.5
4
0.88
0.9

was estimated considering progressive and non-progressive polyp

Comparison of Results

The expected progression time estimates (i.e., Tables 2.6 and 2.7) can be used to
compute one-step transition probabilities needed to build Markov models (as in [1])
for polyp progression. For example, probabilities for R = Caucasian and F = 0 are
depicted in Figure 2.6. We compared the transition probabilities derived from our
model with those compiled by [1], who analyze the cost-effectiveness of screening for
a population without a family history of cancer. Though the study in [1] is based
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Table 2.7. Mean times to progress from event i to event j, given R = r and F = f
( λj1 ) on non-polyp pathway
i|rf

event i → event j
in-situ → local
local → regional
regional → distant

All Races
F >0
F =0
3.4
3.3
3.5
4.8
0.9
0.95

R = Caucasian
F >0
F =0
3.4
3.4
4
4.5
0.9
0.95

R = African American
F >0
F =0
3.1
3.1
3.5
3.5
0.9
0.9

Table 2.8. One-step transition probabilities between stages: Comparing results presented in this research to literature presented in [1]
Literature (Leshno et. al. (2003))
From → To Stages
Transition Probability
low-risk polyp → high risk polyp
0.02

This research
From → To Stages
Transition Probability
p5 → polyp≥1cm
0.035

high-risk polyp → local CRC

0.05 (0.02-0.10)

polyp≥1cm → local CRC

local CRC → regional CRC

0.28 (0.20-0.35)

local CRC → regional CRC

0.20

regional CRC → distant CRC

0.63 (0.50-0.70)

regional CRC → distant CRC

0.65

0.06

on the population of Israel, the reason for our comparison is to only check if our
estimates are within commonly observed ranges, and is not meant as a validation.
The polyp stages considered in [1] are low risk polyps (<1cm), high risk (≥1cm)
polyps, local CRC, regional CRC, and distant CRC, which, as seen in Figure 2.6, are
slightly different from that in our model. Therefore, to obtain a rough comparison, we
assumed equal progression time between stages p5 and S (see pathway 1 in Figure 2.1),
and computed the transition probability from p5 to polyp≥1cm. As shown in Table
2.8, for similar stages (i.e., rows 2, 3, and 4), the transition probabilities obtained
from our model are comparable to that assumed in [1]. Using our mathematical
modeling approach of progression rate estimation, we can further compute populationspecific transition probabilities to build Markov models for developing effective CRC
intervention strategies.

Figure 2.6. One-step transition probabilities for polyp pathway 1 (R= Caucasian,
F =0)
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2.4

Validation of Progression Rates Estimated from Probability Model
In order to validate the progression rates estimated in Section 2.2, we used a sim-

ulation based approach as follows. A simulation model was constructed such that
it initially generates a population based on a user-input demographics data of specific populations. For validation purpose, we considered two different populations:
population of the State of Indiana and population of the clinical trial described in
[37, 38, 39], that was conducted in the State of Minnesota. Further, the simulation
model was built such that it executes the following three events every year for each
person in the population: event 1 ) updating age of each person, and creating new
births and generating mortalities in the population; event 2 ) the natural incidence
and progression of polyps using values presented in Tables 2.4 through 2.7; and event
3 ) screening based on the actual compliance rates of the corresponding population.
Note that, based on change in age (through event 1), event 2 generates polyps and
handles its natural progression until a successful screen (through event 3) leads to
the polyp’s diagnosis. The number and stage of the new cases of polyps that are diagnosed each year are recorded. For validation, the simulated statistics on diagnosed
cases of CRCs are compared with the actual statistics of the corresponding population. The simulation model was constructed in Repast ([40]), a java agent-based
modeling framework. The reason for using an agent-based approach is for ease of including the behavior and interaction between the system entities (including physician
and insurance policies), which is a part of our future research for obtaining cancer
intervention strategies. Simulation events 2 and 3, that were mentioned above, are
described using flowcharts in Figures 2.7 and 2.8. We present below the details of the
validation on the two populations.
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Figure 2.7. Flowchart of simulation Event 2: Incidence and progression of polyps
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Figure 2.8. Flowchart of simulation Event 3: Screening
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2.4.1

Simulation of the Indiana Population

The actual proportion of population in different race, sex, and age groups, as estimated from census data, was used to generate an initial sample population for the
State of Indiana. The mortality and birth rates required for event 1 were also obtained
from the census data. The incidence and progression rates required for event 2 were
obtained from Tables 2.4 through 2.7. The screening rates required for event 3 were
computed using the data obtained through a survey, which was conducted in year
2001 by the Indiana State Department of Health as part of the Behavioral Risk Factor Surveillance System ([2]). The survey considered three screening options: FOBT
(fecal occult blood test), colonoscopy, and sigmoidoscopy. The sensitivity and specificity of the screening tests were taken from the values used in an intervention study
conducted in year 2006 ([3]), and were also used in the MISCAN-Colon microsimulation model ([9]). The values of the screening parameters used in the simulation are
summarized below.

2.4.1.1

Screening Parameters

The parameters used for percentage of population compliant to screening, screening sensitivity and specificity are summarized below in Tables 2.9, 2.10, and 2.11.

Table 2.9. Percentage of population compliant to screening ([2])
Screening Type
FOBT
Sigmoidoscopy
Colonoscopy
NeverCompliant

Percentage Compliant
43
19
19
19
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Table 2.10. Screening sensitivity ([3])
Stage
poly<5mm
poly6-9mm
poly>1cm
in-situ
invasive CRC

FOBT
0.02
0.02
0.05
0.05
0.60

Sigmoidoscopy
0.75
0.85
0.95
0.95
0.95

Colonoscopy
0.80
0.85
0.95
0.95
0.95

Table 2.11. Screening specificity ([3])
FOBT
0.98

2.4.1.2

Sigmoidoscopy
0.95

Colonoscopy
0.90

Assigning Family History Status

For each person in the simulation, we need to determine the family history status.
We assume that F ∼ P oisson(µr ) as described earlier while estimating P {F =
f ∩ R = r} in Section 2.2.1. Note that, the CRC proportion (i.e.,

N umberof CRCcases
T otalpopulation

in

each race) for the State of Indiana is equivalent to the National proportion. Also, the
average family size for the State of Indiana is 3.05 which is approximately equal to the
National average (see estimation of P {F = f ∩R = r} in Section 2.2.1). Therefore, to
generate random numbers in the simulation, we use µr as presented in Section 2.2.1.
The simulation was run with a sample population of 10,000 for 30 trials. As
presented in Tables 2.12 and 2.13, the confidence interval (CI) of the simulated results,
related to new cases of CRCs diagnosed over 5 years, were compared with the actual
2000-2004 diagnosed cases of CRC available on the Indiana State Department of
Health website ([27, 36]). Table 2.12 presents CRC counts per 100,000 of population.
The large range in CI for the African American population can be attributed to its
small percentage (8%) of the total population of Indiana. Table 2.13 presents the
percentage distribution of CRCs among various stages at the time of diagnosis. As
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can be seen in both tables, the actual values lie in between the simulated CI. Note
that, some of the actual values in Table 2.13 fall on the boundary of the simulated
CI, which can be attributed to the fact that about 6.5% of actual CRC cases did
not have a stage identifier (un-staged). It may be noted that Table 2.13 serves as a
verification because, the percentage distribution of diagnosed CRC in different stages
was initially used in the probability model. However, Table 2.12 serves as a validation,
as the simulated CRC results presented in the Table are not equivalent to the cancer
prevalence probabilities (P {C˜t2 } estimated using [33]) that were initially used in the
probability model. The difference between the two is that:
1. The cancer prevalence probabilities used in the probability model were estimated using data from clinical trial studies (not from Indiana database). However, we compare the simulated diagnosed cancer counts with the actual diagnosed counts in Indiana.
2. The second difference is inherent in clinical trial rates versus actual diagnosed
counts itself. The former statistic includes all cases of cancer in the population,
since, in a clinical trial, all participants get screened (ignoring screen sensitivity
which is the same in both cases). However, the latter statistic does not include
all cases, since, in an actual population, not everyone is compliant to screening.
Therefore, the accuracy of the simulated diagnosed cancer counts are dependent on
the population’s screening compliance rates as well as the polyp natural incidence
rates and expected progression times estimated from the probability model. Since the
compliance rates were computed from the Indiana population database, the results
in Table 2.12 serve as a validation of the probability model.
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Table 2.12. Simulated vs. actual Indiana CRC counts per 100,000 of population
Simulated 95% CI
Lower CI
Upper CI
48.83
57.55

Stages

Race
All Race

local + regional + distant

Caucasian
African American
All Race

in-situ + local + regional + distant

52.50
31.97
52.98

Actual Indiana Counts
56.02

61.97
56.53
61.90

57.68
47.93
60.70

Table 2.13. Simulated vs. actual Indiana values for stage at time of diagnosis as
percentage of total CRC counts
CRC Stage
in-situ
local
regional
distant
un-staged
NA- Not Applicable

2.4.1.3

Simulated 95% CI
Lower CI
Upper CI
6.02
9.04
34.99
41.88
29.58
36.75
17.99
23.76
NA
NA

Actual Indiana Values
7.70
34.94
33.75
17.12
6.50

Results from the Simulation Model

The above simulation model was developed to validate the probability model.
However, the combination of the probability model followed by the simulation, as
constructed in this research, serves as a model in itself for obtaining certain polyp
related estimates of interest. One such set of estimates is related to the progressive
polyps. The simulated CIs on the maximum likelihood estimate of the exponential
distribution parameter, i.e., on the mean time to progress (in years) from p5 to S
given R = Caucasian, are presented in Table 2.14. It may be seen that, our estimated value for the progression from polyp≤5mm to in-situ CRC (row 1 of the Table)
compares well with expert opinion in ([18]), where, an average time of approximately
10 years to progress from adenomatous polyp (mainly <1cm) to invasive CRC (local CRC and beyond) is suggested. Use of a mathematical modeling approach for
estimating population-specific values, as in this research, allows us to quantify any
variations across populations. See, for example, Table 2.14, which shows shorter progression time to cancer for a population with F > 0. We also obtained results for the
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proportion of polyp≤5mm progressing to in-situ CRC (i.e., proportion of progressive
polyps), which are presented in Table 2.15 for R = Caucasian. Note that, the proportion of progressive polyps in a population with F > 0 is approximately 1.8 times
as much as that in a population with F = 0. Though it known that a family history
of CRC increases the life-time chances of cancer, such mathematical quantifications
(Tables 2.14 and 2.15) of polyp progression could not be found in the literature.
Table 2.14. Estimated confidence interval on mean time to progress from polyp≤5mm
to in-situ CRC (in years) according to family history

a

Family History(F)
Alla
F =0
F >0
includes F = 0 and F > 0

Upper 95% CI
10.7
12.1
9.9

Lower 95% CI
8.3
9.4
7.7

Table 2.15. Estimated proportion of p5 ’s progressing to S

a

2.4.2

Family History(F )
Alla
F =0
F >0
includes F = 0 and F > 0

Proportion (in %)
20.9
19.5
34.2

Simulation of Minnesota Study

The authors in [37, 38, 39] present a clinical trial conducted in Minnesota, where
a population in age group 50-80 years with no history of cancer was recruited and
randomly divided into 3 groups. Groups 1 and 2 were subject to annual and biennial
FOBT screening, respectively, and group 3 was a control group. The objective of
the study was to identify the difference in CRC related mortality rates among the
three groups, and hence analyze the effect of annual and biennial FOBT screening on
mortalities. Phase I of the study was conducted from 1978 to 1982, and continued to
Phase II from Feb 1986 to Feb 1992. Study groups 1 and 2 were simulated, separately,
by utilizing the values for proportions of people in age ranges 50-59, 60-69, and 70-80
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that were given by [37], as follows. The simulation first generated people between age
0-30 years, with proportions of people in age ranges 0-9, 10-19, and 20-30 equal to the
proportions of people in age ranges 50-59, 60-69, and 70-80, respectively, of the actual
study. The simulation was first run for 50 years so that the population is now between
age group 50-80 years, and then later run for a period of 14 years representing the
timeline of the actual clinical trial. The mortality and birth rates (event 1) were kept
at zero during the first 50 years. Event 2, i.e., polyp incidence and progression was
run during the entire period, and for which the rates were obtained from Tables 2.4
through 2.7. During the first 50 years, any symptomatic cases of CRC were removed
from the simulation in order to remove existing diagnosed cases of cancer, and the
proportion of population in the three age groups were adjusted. The exponential mean
time to symptomatic was taken as per the times (preclinical to clinical) considered
in the MISCAN-colon model ([10]), whose parameters, as mentioned earlier, were
based on expert estimates presented in meetings at the National Cancer Institute.
During the 14 year run that represented the actual study, study groups 1 and 2 were
subject to annual and biennial screening, respectively, as per screening details and
test sensitivity provided by [37] (event 3).
The simulated cases of CRC during 13 years of the study were compared with
the actual cases given by [37] and the results (represented as CRC cases per 1000
population) are presented in Figures 2.9 and 2.10 for annual and biennial screening
groups, respectively. Since the simulated screening intervals matched that in the
clinical trial, the accuracy of the simulated CRC cases is dependent on the natural
polyp progression, whose rates were estimated from the probability model. Moreover,
tracking a population and comparing results over a 13 year period is a stronger
analysis of the polyp progression, and therefore, Figures 2.9 and 2.10 can be used for
validating the probability model.
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Figure 2.9. Comparing simulated versus actual CRC cases per 1000 population for
annual group of the Minnesota study
As seen in the Figures, there is a good agreement between the actual and simulated
values, with only slight deviations in the annual case. While the actual values for
biennial group falls within the simulated 95% confidence interval in most years, the
actual values for annual group are lower during Phase 1 of the study and higher
during Phase II of study. The aforementioned deviations in values can be explained
as follows.
1. Lack of data on the number of screenings: It is noted by [37] that not everyone
participated in the scheduled number of screens, which was 11 for annual group
and 6 for biennial group ([38]) over the entire duration of study. For each person,
let X= number of screens obtained during study duration. Using information
provided for each group in the study, data could be extracted for the following
features: for annual group - percentage of people with X ≥ 1, X ≥ 6, X ≥ 9,
and X = 11; and for biennial group - percentage of people with X ≥ 1, X ≥ 3,
X ≥ 5, and X = 6. Note that, when we compare the information available
for X between the two groups, biennial group has more information compared
to that of annual group. Under the biennial group, the extracted information
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Figure 2.10. Comparing simulated versus actual CRC cases per 1000 population for
biennial group of the Minnesota study
was used to obtain probability that X = 1 or 2, i.e., P (1 ≤ X ≤ 2), and was
split uniformly between P (X = 1) and P (X = 2), and similarly P (3 ≤ X ≤ 4)
was split between P (X = 3) and P (X = 4). However, under the annual group,
P (1 ≤ X ≤ 5), P (6 ≤ X ≤ 8), and P (9 ≤ X ≤ 10) had to be split between
5, 3, and 2 values of X, respectively. This lack of information for annual group
can be considered to partly account for the difference in simulated to actual
values. Also, under both groups, if an individual had participated in n number
of screens, it was assumed that it was the first n of the scheduled screens, while
in reality the screenings could have been spread over the period of study. We
can expect that this assumption will cause greater and noticeable difference,
between simulated and actual values, for the annual group than the biennial
group because, e.g., X = 5 under biennial screening is spread over only 6
possible screening schedules while X = 5 under annual screening is spread over
11 possible screening schedules. From the assumption stated above and lack of
data for the annual screen, we can expect that there will be more than actual
number of screens during the initial period of study and hence more CRCs
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get diagnosed in the simulation. Further, we can also expect that, along with
causing lesser than actual number of screens during the latter period of study,
increased screening in the beginning reduces the number of polyps that progress
to CRC, and hence further reducing CRC incidence during the latter period.
This is evident in Figure 2.9.
2. Lack of information on screening outside of the study: As mentioned in the
study, participants could have obtained screening from a source outside the
study during and in-between the two phases, and yearly updates were obtained
on any diagnosed cases of CRC. Since information on outside screening was not
available, it was assumed that a person undergoes screening outside of study
in symptomatic cases only. The time to symptomatic was extracted from the
MISCAN-colon parameters presented in [10]. The above assumption together
with the fact that advanced stages of CRC tend to be more symptomatic than
earlier stages, we can expect that, while comparing simulated minus actual CRC
cases per stage at diagnosis, the value will be higher for distant stage compared
to regional compared to local. This trend is evident in Tables 2.16 and 2.17,
for annual and biennial groups, respectively, which presents the CRC cases per
1000 population according to stage at diagnosis over the 13 year period. Note
that, in the clinical trial, staging of CRC was done by using Dukes classification.
We considered Dukes stages A and B as equivalent to local, and Dukes stages
C and D as equivalent to regional and distant, respectively.
Based on our assumptions 1) that an individual undergoes the first n of the scheduled screens, and 2) that outside screening was done only in symptomatic cases, we
can hypothesize that the percentages of diagnosed CRCs in stages regional and distant
are more during the latter period of study compared to those in the initial period.
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Table 2.16. CRC counts per 1000 population and stage at diagnosis - For annually
screened group of Minnesota study
Simulated 95% CI
CRC Stage
Lower CI
Upper CI
local
8.83
9.76
regional
4.64
5.36
distant
2.87
3.56
un-staged
NA
NA
Total CRC
16.34
18.68

Actual Counts
Dukes CRC Staging Actual Values
A+B
13.3
C
5.6
D
2.3
un-staged
2.1
Total CRC
23.3

Table 2.17. CRC counts per 1000 population and stage at diagnosis - For biennially
screened group of Minnesota study
Simulated 95% CI
CRC Stage
Lower CI
Upper CI
local
9.51
10.76
regional
6.77
7.73
distant
4.66
5.49
un-staged
NA
NA
Total CRC
20.94
23.98

Actual Counts
Dukes CRC Staging Actual Values
A+B
11.6
C
6.1
D
3
un-staged
2.1
Total CRC
22.8

The reasoning leading to the hypothesis can be explained as follows. Assumption
1 generates more than actual screenings during the initial few years, thus causing
less cases to reach a symptomatic stage. Consequently, the latter duration has lesser
than actual number of screens causing more cases to reach symptomatic stage. Since
advanced stages of CRC are more symptomatic than earlier stages, we can thus hypothesize that, the consequence of assumption 1 combined with assumption 2 causes
diagnosis of greater percentage of regional and distant cases during latter period of
study compared to initial period. This hypothesis can be verified by the numbers in
Tables 2.18 and 2.19. As speculated, the percentage of CRCs in regional and distant
stage is higher at the end of year 13 compared to that at the end of year 5.

2.5

Concluding Remarks
Precise values of polyp incidence and progression rates are crucial for developing

population-wide CRC intervention strategies. Polyp incidence rates for population
groups characterized by age, race, and family history of CRC, were estimated by using
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Table 2.18. Stage at diagnosis as percentage of total CRC counts - For annual group
of Minnesota study
CRC Stage
local
regional
distant
un-staged

Simulated 95% CI
End of 5 Years
End of 13 Years
Lower CI
Upper CI
Lower CI
Upper CI
58.57
64.63
51.20
55.24
20.99
26.60
27.07
29.86
12.43
16.78
16.62
20.00
NA
NA
NA
NA

Actual Values
End of 13 Years
Dukes CRC Staging
Actual Values
A+B
57.08
C
24.03
D
9.87
un-staged
9.01

Table 2.19. Stage at diagnosis as percentage of total CRC counts - For biennial group
of Minnesota study
CRC Stage
local
regional
distant
un-staged

Simulated 95% CI
End of 5 Years
End of 13 Years
Lower CI
Upper CI
Lower CI
Upper CI
48.34
53.56
43.28
46.70
28.93
34.35
30.48
34.29
15.13
19.70
20.88
24.36
NA
NA
NA
NA

Actual Values
End of 13 Years
Dukes CRC Staging
Actual Values
A+B
50.88
C
26.75
D
13.16
un-staged
9.21

data from the literature. The data sources included clinical CRC screening trials,
population databases, and evidence-based reports from state health departments and
national institutes. The natural progression timeline of polyps, on the other hand,
could not be directly estimated using observed data, since it is infeasible to allow
a diagnosed polyp to progress naturally without treatment. Hence, we developed
a probability model to estimate population-specific rates of polyp progression. The
probability model was constructed based on known concepts of the natural progression
of polyps. Thereafter, using the model, data from the above mentioned sources were
synthesized to estimate progression rates. These rates are characterized by race and
family history of CRC and correspond to both progressive and non-progressive polyps.
The estimated incidence and progression rates (presented in Tables 2.4 through 2.7)
were used to simulate the natural history of colorectal polyps for the population in
the State of Indiana and a subset of the population in the State of Minnesota. The
simulation results were used to validate the probability model. The simulation model
also yielded 1) the expected time for progressive polyps to reach in-situ CRC from
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the polyp≤5mm stage, and 2) the proportion of polyps reaching in-situ CRC (i.e.,
progressive polyps). Tables 2.14 and 2.15 present results for the progression time and
proportion of the progressive polyps for population with and without family history
of CRC.

2.5.1

Discussion of Results

The polyp progression related values available in the literature are mainly experience based approximations and are not population-specific. Though the literature contains several data sources related to the incidence of either precancerous
polyp or carcinoma, these data had not been synthesized to mathematically estimate
population-specific polyp progression times (as in Tables 2.6 and 2.7). Mathematical
estimation will help identify and quantify any variation across populations which are
critical for developing early intervention strategies.
The probability model was developed to estimate rates considering both progressive and non-progressive polyps, and was subsequently used in the simulation model
to obtain statistics of progressive polyps. Such an approach is significant, since, while
it is known that a family history of CRC increases the risk of cancer, quantification
of the increased risk based on proportion of progressive polyps (as in Table 2.15) has
not been presented in the literature. Also, the risk based on progression time from
polyp≤5mm to in-situ CRC had not been mathematically quantified, as in Table
2.14. Consideration of both progressive and non-progressive polyps also supports development of more comprehensive intervention strategies comprising resource needs
and allocation.
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2.5.2

Accuracy and Estimation Errors

Though our model estimates polyp progression rates specific to race and family
history of CRC, for better accuracy of the estimates, it is essential that the model be
expanded to consider other dependent factors. Examples of dependent factors include,
number and histology of polyps, classification of first and second degree relatives with
CRC, and personal history of other medical conditions. However, inclusion of these
factors in the model would require significant additional data, which is currently
unavailable. Also, estimating progression rates between each of the pre-in-situ stages
would help to simulate a more comprehensive natural progression of polyps. As in
any estimated value, the progression rates presented in this manuscript could contain
some error. While synthesizing data from various sources is beneficial for estimating
the rates, the variation in the data acquisition processes across these sources could
induce some estimation error. For example, the value of P {F > 0|p5t1 } was estimated
based on diagnosed data at the Rochester Methodist hospital ([25]). However, the
value of P {F > 0|C˜t2 } was estimated based on expert observation reported by the
American Cancer Society. Since these values were based on either large amount of
data or long-term observations, we expect the error to be relatively small. Due to
the unavailability of required data, some of the values were based on assumptions,
hence creating room for estimation error. For example, based on expert opinion in
the literature, the time to progress was assumed to follow exponential distribution.
Though we cannot empirically ascertain this assumption, based on the validation
results, we believe that the exponential distribution is a good alternative. It may
be noted that, this research presents a model framework that has the potential to
estimate population-specific progression rates the accuracy of which can be improved
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as more data becomes available. Such a model is significant for obtaining populationspecific intervention strategies.

2.6

Future Research
Obtaining effective cancer intervention strategies encompasses not only develop-

ment of screening strategies, but also analyzing factors pertaining to the availability
of resources such as the patient’s access to physician and hospital, and effective dissemination of evidence based information to the population. For example, it would be
useful to assess the population’s compliance to screening guidelines based on features
like the patient’s knowledge of cancer screening tests and cancer risk factors. This
knowledge can be related to the patient’s access to information through interaction
with their physician and/or through other sources. The model can then be used for
a cost-effectiveness analysis of programs to increase risk awareness and its impact on
reduction in cancer cases. It would also be interesting to model the impact of insurance policies under different system settings. Therefore, in addition to simulating the
population entity, we need to include entities like physicians and insurance policies,
and their interactions. Note that, the current simulation model has been constructed
as an agent-based model for the convenience of developing such a system-based simulation, which is part of our future research. Such a systems approach will allow for
a more realistic analysis of feasible intervention strategies.
In summary, the probability model in the current state can be considered a base
model that presents potential for use in developing population-specific intervention
strategies. The work presented here can be used to support the need for collection
of specific data required for analyzing and identifying more population-specific factors of interest. While the model developed in this manuscript has been specifically
applied to colorectal cancer, most diseases follow a similar pattern, i.e., incidence
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and progression. Following a similar procedure, but with disease specific modeling
details, the current framework could be utilized for estimating progression and developing intervention strategies for other cancers as well. In addition, by inclusion of
a transmission model in the current framework, cost-effective analysis of prevention
programs for infectious diseases like HIV/AIDS could be developed.
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CHAPTER 3
A DENOISING METHODOLOGY FOR MICROARRAY

3.1

Introduction
Discovery of the human genome generated significant anticipation for better un-

derstanding of the roles played by the genes on cell behavior and the resulting impact
on human health [41, 42]. Most diseases result from cell dysfunction, which can be
traced to alteration in the structure of one or more genes (biomarkers). Alterations
could be in the form of abnormal increase or decrease in the expression (activity)
levels of genes and their patterns. Identifying different patterns in biomarker genes
could hold the key to disease diagnosis and individualized treatment planning, which
is of vital interest as identified by the National Academy of Engineering under one
of the Grand Challenges- Engineering Better Medicine. Hence, our ability to first
accurately measure the expression levels of the genes is crucial towards identifying
gene biomarkers. The microarray technology has revolutionized the field of genomics
by offering the capability to measure expression levels of tens of thousands of genes
simultaneously. However, during the process of gene expression estimation, noise
from various sources gets added to the expression value. The noise generally originates during the phases of sample preparation, hybridization, and scanning [43]. The
sample preparation noise initiates from the process of RNA amplification [44], and
the hybridization noise refers to the randomness in the process of RNA binding to
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the probes. The sources of scanning noise include leak of external light, variations in
laser intensity, and presence of dirt [45, 43].
A microarray is a tiny chip (1.28cm X 1.28cm) which is divided into approximately
a million squares which we will refer to as probe squares. A number of such probe
squares across the array are randomly allocated to each gene [44]. The complexity of
the arrangement of microarray probes and the types of inherent noise render a significant challenge for denoising. Some of the existing methods for denoising microarray
data can be found in [46, 47, 48, 49, 50, 51]. In [46] the authors develop statistical models for analyzing hybridization and cross-hybridization, and use measures of
cross-hybridization to improve the quality of gene expression estimates. A probability
model characterizing the nature of molecular-binding (hybridization) in affinity based
biosensors is presented in [47]. The methodology developed in [48] employs a multiresolution approach, in which a 2-D stationary wavelet transform is applied across
a microarray image. Various other methodologies [49, 50, 51], focus on denoising
of microarrays involved in identifying differentially expressed genes. These methods
generally require multiple arrays or two-color microarrays. Noise boundary models
are developed in [49] using two replicate chips of normal tissues, and the resulting
threshold boundaries are applied on fold change obtained between cancer tissue and
normal tissue. Two-color microarrays are denoised in [51] by considering the control
and experimental sets as two component vector arrays and use multi-channel image
processing techniques.
The disadvantages in the use of control sample based approaches of denoising are
as follows.
1. Use of such methods, that require processing of up to two additional microarray
chips, adds significant cost (over a thousand dollars) in disease diagnosis and
treatment planning applications.
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2. During microarray chip processing, different amounts of hybridization and scanning noise get added each time the process is performed, even under a controlled
environment. Therefore, when two replicate chips of control samples are processed, the difference in their gene expressions is a result of noise that are specific
to the images of the two chips. Hence, the difference in gene expressions of the
control images cannot be used to derive a noise threshold for denoising other
microarray images, since they are likely to contain different sets of noise.
3. In methods that use the difference in final gene expression values, between
control and case samples, it is difficult to differentiate noise from actual signal
for the case of low expressed genes. That is, while significant difference in high
expressed genes can be easily identified, significant difference in low expressed
genes could be falsely classified as noise.
We present a novel and comprehensive methodology for removing hybridization
and scanning noises from Affymetrix microarray images before the image data is processed by Affymetrix software to obtain final gene expression values. The method
uses data from within the image that needs to be denoised and does not require
control samples. Since noise arises from a variety of sources, the methodology uses
a multiresolution analysis approach on the image to effectively isolate the noise at
different frequencies. The image is decomposed using a dual tree complex wavelet
transform, which is shown to have better properties with regard to shift invariance,
directional selectivity, and perfect reconstruction, compared to transforms using real
wavelet functions [52]. Natural images are generally known to contain a small number of edges, and hence when it is decomposed at different frequencies it results in
a small number of large coefficients [53, 54]. This facilitates the process of separation of noise from significant data using thresholding [53]. It was noticed that a
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similar direct use of the existing multiresolution denoising technique was ineffective
when applied to microarray images. We identified two major features of microarray
images that were the cause of the ineffectiveness: 1) presence of numerous edges in
microarray images results in a vast number of large coefficients during decomposition,
hence hindering the noise separation, and 2) non-Gaussian (Poisson) characteristic of
the hybridization noise added to the denoising inefficiency, since most thresholding
methods require error to be Gaussian. A more detailed discussion of the topics of
presence of numerous edges and Poisson noise in microarray images is presented in
Section 3.2.2. To alleviate the above difficulties, we developed two forms of data
transformations: 1) extraction of the probe squares that are assigned to a gene on
a microarray, and construction of a separate dyadic subimage for each gene, and 2)
for each subimage, Gaussian transformation of the Poisson noise. For each modified
subimage data, we apply a dual tree complex wavelet transform followed by bivariate
shrinkage thresholding. The thresholding technique underlying the bivariate shrinkage method considers the interdependencies of the detail coefficients in adjacent levels
of decomposition producing better performance [55]. Thereafter, the denoised version of the microarray image is created using the probe squares from the denoised
subimages. Final expression values of the genes are obtained from the probes using
Affymetrix software.
Since it is not possible to know the true values (ground truth) of the expression
levels of the genes for a tissue sample, it is difficult to assess the performance of
denoising on a microarray. We address this problem by constructing a sample data
set mimicking a subimage for a gene, and use it to benchmark our methodology. We
then implement our methodology on Affymetrix GeneChip human genome HG-U133
Plus 2.0 array [56] data sets, obtained by processing a sample from HCT-116 cell line
at the Microarray Core Facility at Moffitt Cancer Center and Research Institute. Each
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HG-U133 Plus 2.0 array contains about 1.3 million probes and is used to measure
expressions of the entire human genome (about 38,500 established genes). A chip
is processed on the cell line and multiple scans of the chip are obtained. Using
these multiple datasets we conduct statistical comparisons to establish the denoising
performance.
In summary, the contributions of the methodology include 1) identification of
distinguishing features between microarray images and natural images, i.e., features
that were the cause of ineffective denoising, 2) obtaining a strategy for reconfiguring
microarray images to resemble natural images, and 3) developing a strategy for estimating noise parameters from within the microarray image being denoised (which
obviates the high cost of using images from multiple chips and hence, eliminates the
influence of different noise unique to the respective images). Also, estimating noise
by the use of multiple instances (probesquares) of the same gene, from within the raw
image, will avoid removal of valid data.

3.2

A Novel Denoising Methodology for Microarrays
Both hybridization and scanning noise in microarrays are inherently nonuniform

across a microarray, and hence are localized in space. Also, due to the variety of their
sources, they appear at different frequencies. These frequency and space localizations
make microarray noise an ideal candidate for wavelet based multiresolution analysis.
Prior to the presentation of our methodology, we provide, for unfamiliar readers, a
brief outline of the 2-D wavelet decomposition technique and the properties of a dual
tree complex wavelet transform.
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3.2.1

Overview of Wavelet Based Multiresolution Analysis

Wavelet’s multiresolution approach to data representation has been a major breakthrough in the field of signal processing. Its applications range from data compression,
data denoising, to real-time process monitoring [57, 58]. Wavelets consist of basis
functions, where, a basis is made up of a scaling function (Φ) and a mother wavelet
(Ψ). The mother wavelet is a short wave and therefore has its energy localized in
time, unlike sinusoids in Fourier transforms. A one-dimensional signal g(t) can be
represented by translations of a scaling function and translations and dilations of the
mother wavelet as follows.

g(t) =

X

cj0 ;k Φj0 ;k (t) +

X X

dj;k Ψj;k (t)

j≥j0 k∈Z

k∈Z

where, Φj0 ;k (t) = 2j0 /2 Φ(2j0 t−k), Ψj;k (t) = 2j/2 Ψ(2j t−k), and j = j0 , j0 +1, ....; k ∈ Z,
where Z is a set of integers. Translation is a shift in the location of the function
along the axis and is represented by change in the value of k. Dilations or change
in frequency, represented by j, are attained by change in the width of the wavelet
function. Wavelet transforms use scaling (low pass filter) and wavelet (high pass
filter) functions to decompose a signal at different resolutions or scales and obtain
their scaling coefficients, cj0 ,k (approximations), and wavelet coefficients, dj,k (details),
respectively. Two-dimensional signals (images) are decomposed by passing the signal
through low and high pass filters on the rows of the signal, the output of which is
again passed through low and high pass filters on the columns. This leads to the
creation of horizontal, vertical, and diagonal detail coefficients as shown below.

g(x, y) =

X

cj0 ;k,l Φj0 ;k,l (x, y) +

XX X
i j≥j0 k,l∈Z

k,l∈Z
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(i)

(i)

dj;k,l Ψj;k,l (x, y)

where, k ∈ Z and l ∈ Z are translation indices along x and y axes respectively. The
scaling function Φj0 ;k,l (x, y) is obtained by the tensor product of the scaling functions
applied on the rows and columns respectively, which is written as Φ(x)

N

Φ(y). The

detail functions are obtained as follows.
(1)

N

Ψ(y)

Horizontal Detail

(2)

N

Φ(y)

Vertical Detail

(3)

N

Ψ(y)

Diagonal Detail

Ψj;k,l (x, y) = Φ(x)

Ψj;k,l (x, y) = Ψ(x)

Ψj;k,l (x, y) = Ψ(x)

Since wavelets are localized in space and frequency, the wavelet coefficients obtained from decomposition contain a few large values and a large number of small
values [53, 54]. This is an important property of wavelet decomposition and holds the
key to the application of wavelets in signal denoising. Signals are decomposed using
wavelets, and denoising is achieved by employing thresholding methods for identification of significant large coefficients, and for removal of noisy parts. The coefficients
are then reconstructed to obtain noise free signal.
Discrete wavelet transforms use wavelets that are real. After decomposition of an
image, the approximation and detail coefficients obtained are each equal to the original length of the signal. Hence, the signal is downsampled to remove odd-numbered
coefficients. This alters the shift invariance property. That is, if there is a shift in the
input signal, wavelet coefficients at different scales undergo a major change in energy
distribution. Use of real wavelets cause another problem called directional selectivity. It is known that detail coefficients contain energy distributed in both positive
and negative gradients. However, it is not possible to differentiate between the two
orientations as all gradients are obtained as output from a single filter [52]. Com54

plex wavelets can be used to overcome these drawbacks. In complex wavelets, the
phases vary approximately linearly with input shift and can be designed such that the
magnitudes vary very slowly, thus making them approximately shift invariant [52].
Output from complex wavelet contain complex coefficients since the complex filters
either emphasize on positive frequencies and reject negative frequencies, or vice-versa,
thus achieving directional selectivity. However, while using complex wavelets, if we
decompose an image to more than one level, we cannot achieve perfect reconstruction
[52]. Use of dual tree complex wavelet transform (DT CWT) alleviates the above
problem and at the same time achieves shift invariance and directional selectivity. In
what follows, brief descriptions of DT CWT and a bivariate shrinkage thresholding
technique that is used in our denoising methodology are presented.

3.2.1.1

Dual-Tree Complex Wavelet Transform

DT CWT uses the concept that shift invariance can be achieved for real DWT by
eliminating down-sampling ([52]). However, instead of eliminating down-sampling,
DT CWT achieves shift invariance by using two parallel fully decimated trees where
the delays of the filters in the second tree are one sample offset from the first at
level one and half a sample different at further levels [52, 59]. This construction also
offers the perfect reconstruction property. The dual tree transform is interpreted as
a complex transform by considering the outputs from the two trees as real and imaginary parts of complex wavelet coefficients. This also offers DT CWT the directional
selectivity property [52].

3.2.1.2

Bivariate Shrinkage Thresholding

For any thresholding technique, the amount of noise removed is dependent on its
ability to identify the coefficients that relates to noise. A feature that distinguishes
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Bivariate Shrinkage (BiShrink) method ([55]) from other potential thresholding techniques that are available in the literature is the consideration of interscale dependency property of detail coefficients. It is well known that large/small value of the
wavelet coefficients usually propagate through the scales [55, 53]. BiShrink method
generates models to identify this interdependency between adjacent scales. Using
maximum likelihood estimators for the variance of noise and that of data at two adjacent scales, and assuming noise to be Gaussian(0, σ), the BiShrink method estimates
noise-free values of the detail coefficients using maximum a posterior (MAP) estimators ([55](Model 3)). A study performed on DT CWT decomposed image coefficients
([55]) demonstrates that bivariate shrinkage exhibit better denoising performance
compared to other thresholding methods.

3.2.2

Microarray Denoising Methodology

In multiresolution based denoising, the image is decomposed using the selected
wavelet basis followed by application of the thresholding strategy. However, microarray image denoising cannot follow a similar procedure due to the difficulties related
to large number of edges and non-Gaussian noise, and hence, two different strategies
were developed. Before giving a detailed description of the two features of microarray
images and the two developed strategies, we give a brief overview of a microarray
chip, cRNA extraction, and hybridization of cRNAs to DNA strands.

3.2.2.1

Microarray Chip

A DNA Microarray, for example, a GeneChip human genome HG-U133 Plus 2.0
array, is divided into over 1,300,000 minute squares called probes [56]. Each probe
square is embedded with millions of copies of a short DNA strand that correspond to
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a single gene. The 1.3 million probe squares are allocated to over 54,676 genes with
each gene represented in eleven randomly selected probe squares across the chip.

3.2.2.2

cRNA Extraction

RNAs are extracted from the cell sample and synthesized to obtain cDNA (complimentary DNA) and further cRNA. Hence, all genes that are expressed in the cell
will contain its corresponding cRNAs in the extract, with number of cRNAs being
proportional to gene expression. The number of cRNAs in the extract are amplified
to ensure proper hybridization. Molecules of a chemical called biotin are attached to
the cRNA strands.

3.2.2.3

Hybridization of cRNAs to DNA Strands

The cRNA extract is poured over the microarray. If the cRNA finds a matching
DNA strand (hence representing same gene) the cRNA will bind i.e., hybridize to
the strand. Therefore, the extent of hybridization is proportional to the expression
of the gene. A fluorescent stain is then run over the array which sticks to the biotin
that acts as a molecular glue. The microarray is scanned to extract the intensity
of glow which is proportional to extent of hybridization. The millions of strands of
DNA in each probe square are represented by only a small matrix of pixel values,
e.g., 7x7 in HG-U133 Plus 2.0. Each probe square is thus represented by a matrix of
pixels whose intensities represent the extent of hybridization in the region, and hence
the corresponding gene expression value. Thus, a microarray image is comprised of
matrices of intensities of probe squares across the entire chip.
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Figure 3.1. Randomly varying intensities of adjacent probe squares depicts presence
of large number of edges in a microarray image

3.2.2.4

Strategy 1: A Separate Subimage for each Gene

As mentioned above, eleven randomly selected probe squares are allocated to each
of the 54,676 genes. Thus, it is highly likely that adjacent probe squares are allocated
to different genes with varying levels of expression. The pixel intensities of a probe
square are proportional to the extent of cRNA binding, and hence adjacent probe
squares have varying intensities. Also note that, these intensities vary among pixels
even within a probe square[44]. Moreover, a mismatch square is placed below every
probe square assigned to a gene (perfect match) [60]. These mismatch squares are
designed to measure the extent of undesired bindings, and thus have very differing
intensities from that of the perfect match probes. As evident from above, the microarrays, by design, have inherent variations between adjacent probe squares in addition
to the variations within. Thus, the microarray images have a very large number of
edges contrary to natural images. Figure 3.1 shows a schematic representation of
the wide variations in intensity among adjacent probe squares in a microarray. Such
images, with high intensity variations, when decomposed, generate a large number
of high value detail coefficients. Consequently, during thresholding, it becomes difficult to identify the large coefficients that correspond to noise. This results in poor
denoising.
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Our strategy involves separating the microarray image into multiple subimages,
one for each gene, where each subimage is created as a collection of the probesquares
assigned to a gene. The idea behind this strategy is that, intensity variations across
probe squares of the same gene are much less compared to that across probe squares
of different genes. Hence, creating a subimage for each gene will have far less number
of edges compared to that of the original microarray image, thus leading to better
denoising. The subimages are obtained as follows. The library file (CDF file) of the
microarray chip contains a list of all genes along with their i) x and y coordinates of
all corresponding probe squares, and ii) the number of rows and columns of pixels
for each probe square. The DAT file contains the pixel values of the microarray chip.
Using the CDF file, the location of the first probe square of gene 1 is identified and
the corresponding matrix of pixel values is extracted from the DAT file. Similarly
the matrix of pixel values of the remaining probe squares of gene 1 are extracted and
the matrices are placed sequentially row-wise to obtain the subimage in Figure 3.2.
Some of the matrices are repeated to ensure that the subimages are dyadic, which
is a requirement for wavelet based multiresolution analysis. Similar subimages are
obtained for all genes. As depicted in Figure 3.2, the subimages are individually
considered for denoising. After which, the original probe square intensities on the
microarray image are replaced with those extracted from the denoised subimages.
Further analysis of the image, that involve determining the final gene values [60] is
carried out using existing procedures of Affymetrix, namely GCOS and MAS. As
shown in Figure 3.2, the subimage data, prior to decomposition, undergo another
transformation, which is described next.
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Figure 3.2. Construction of a dyadic subimage, transformation of poisson to normal,
denoising and replacing denoised data to reconstruct microarray image

3.2.2.5

Strategy 2: Noise Characterization and Transformation

The noise in gene expression values is a combination of sample preparation noise,
hybridization noise, and scanning noise. Sample preparation noise arises from: inherent inability of the experimental procedure to achieve a target cRNA amplification
rate during cRNA extraction, and variation in the amplification rate among the cRNAs (a Poisson noise [43]). However, sample preparation noise is small in proportion
to the other two noise types. Hybridization noise is attributed to the probabilistic
nature of hybridization and is proportional to the gene expression value (pixel intensity). Such an intensity dependent noise is called shot noise and is known to have a
Poisson distribution. Scanning noise, on the other hand, is independent of expression
values and may be induced by the presence of dirt, reflection of light, and other random causes. Readers are referred to [43] for a detailed characterization of the noise
types. In what follows, we explain our strategy for estimating the noise parameters
using pixel intensities from a single chip that needs to be denoised.
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Isolation of sample preparation noise is not feasible using a single chip, since identifying the noise parameter requires the use of multiple replicates of the same sample.
Moreover, since the magnitude of this error is small, we did not attempt to remove
this noise. The probabilistic variation in hybridization induces Poisson noise in gene
expression values [43]. Hybridization noise arise from two types of binding errors, i)
where a cRNA strand might not bind even when a matching DNA strand is present
(missed binding), and ii) when a cRNA might bind to a non-matching DNA strand
(false binding). Therefore, the number of binding errors per pixel is Poisson distributed. Note that, Poisson distributed random variables take non-negative values,
and therefore we consider the number of binding errors as equal to the absolute value
of the difference between the number of false bindings and the number of missed
bindings. Therefore, for each pixel, the Poisson noise has either been added (when
false binding is the dominating type of binding error) or subtracted (when missed
binding is the dominating type of binding error) from the actual intensity. As is clear
from above, the variation among the pixel intensities within a probe square is also
induced by variation in hybridization. Therefore, we estimate the hybridization noise
Poisson parameter λ from the absolute value of intensity variations among the pixels of a probe square. Also, since the denoising method using BiShrink thresholding
requires that all error is ∼ N (µ, σ 2 ), with µ = 0, we use a normal approximation of
the Poisson distribution. This approximation can be justified as follows. Since each
probe square is represented by a small number of pixels, each pixel reflects a collection
of millions of DNA strands. If we divide these DNA strands into several groups and
consider the number of binding errors for each group, then, the sum of the binding
errors over all groups of the pixel would be normally distributed based on the central
limit theorem. Therefore, we can write that hybridization noise ∼ N (µ, σ 2 ) with,
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µ = λ and σ 2 = λ. The scanning noise, due to the nature of its sources, is assumed
to be Gaussian with mean zero.
In what follows, we describe the estimation of the mean of the hybridization
noise, and then apply a standard normal transformation since, as mentioned earlier,
BiShrink thresholding requires a noise with mean zero. Since hybridization noise is
proportional to intensity, noise estimation was carried out separately for each probe
square within a subimage. Let pn represent the array of pixel intensities of the nth
probe square of a subimage. Each pixel intensity value pn (x, y), where, x and y are
array coordinates, is modeled as follows:

pn (x, y) = E n + nH (x, y) + nS (x, y),

(3.1)

where E n denote the true expression value of the gene as measured by the nth probe
square, nH (x, y) denote the normal transformation of hybridization noise with µ =
λn and σ 2 = λn , and nS (x, y) denote the normal distributed scanning noise with
parameters (0, σ n ). Note that, the hybridization and scanning noises are independent
of each other, where hybridization noise is based on incorrect hybridization, while
scanning noise is caused by external features like presence of dirt. We take the
median of the pixel values of the nth probe square, denoted by Ê n as an estimate of
E n . Define dn (x, y) as
dn (x, y) = pn (x, y) − Ê n .

(3.2)

Then we can write that dn (x, y) contains two normally distributed noise components, sum of which also has a normal distribution with parameters µ = λn and
√
σ = λn + σ n . Note that, as explained earlier, the hybridization noise is a positive
value which is either added or subtracted from E n . Positive values of dn (x, y) denote
pixels where noise has been added, while negative values denote pixels where noise has
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been subtracted. Therefore, to estimate the value of λ using a maximum likelihood
estimate principle, we use the absolute value of dn (x, y), and write that

λn =

1 XX n
|d (x, y)|
N x y

(3.3)

where, N is the size of the array. Note that dn (x, y) contains a combination of
hybridization noise and scanning noise. While scanning noise is considered to have
zero mean, the hybridization noise has a mean of λn . Therefore, in order to obtain
a total noise mean of zero, we apply a standard normal transformation of dn (x, y)
(denoted by dnT (x, y)) as follows
dnT (x, y) =

|dn (x, y)| − λn
√
.
λn

(3.4)

Therefore, dnT (x, y) now contains hybridization noise and scanning noise with a total
sum of mean of zero. Finally, we obtain the modified individual pixel values, denoted
by pnM (x, y), as follows. From pn (x, y), we remove dn (x, y) which contained a non-zero
mean from hybridization error. By retaining the sign of the dn (x, y), hence representing the direction in which hybridization noise was included, we replace dn (x, y) by
dnT (x, y), and write that
pnM (x, y) = pn (x, y) − dn (x, y) + sign(dn (x, y))|dnT (x, y))|.

(3.5)

Therefore, pnM (x, y) now contains the true expression value along with the normally
distributed hybridization and scanning noises, with a total mean noise of zero.
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3.2.3

Steps of the Denoising Procedure

1. Begin with the DAT file of the microarray image and the CDF file of the corresponding chip. The DAT file contains the pixel values, i.e., the raw image data.
The CDF file is the library file that contains a list of genes, the coordinates
of all of its corresponding perfect match and mismatch probe squares, and the
number of rows and columns of each probe square.
2. Using the information on the coordinates and the number of rows and columns
from the CDF file, extract the intensity values of all perfect match (PM) probe
squares of a gene from the DAT file. (In this research, some of the C codes
available at [61], a public software repository, were used for the purpose.)
3. Copy onto a text file the data arrays that represent the probe squares, to form
the rows and columns of a subimage of maximum possible dyadic size. For
example, typically a gene on the GeneChip human genome HG-U133 Plus 2.0
array is represented by 11 PM probe squares where each probe square is (suppose) a 7 × 7 array of intensity values. Therefore, forming a subimage of 3 × 3
probe squares will give us an array of intensity values of size 21 × 21. In order
to make this dyadic i.e., 32 × 32, the first 11 rows and columns are repeated
to form the last 11 rows and columns respectively. Since the subimage thus
created involves only the first 9 out of the 11 PM probe squares of the gene, the
last 9 PM probe squares are used to create another dyadic subimage in a similar
manner (note that 7 probes are included in both subimages). This allows us to
denoise all the probe squares.
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4. Since Poisson noise is proportional to the pixel data intensity, conduct on each
probe square the Gaussian transformation of Poisson noise as given in Equation
(3.5) to create two modified subimages.
5. Denoise each of the two modified subimages by applying a sequence of DT
CWT decomposition, Bivariate Shrinkage, and reconstruction, using the software available at [62].
6. Replace the data in the DAT file that corresponds to the PM probe squares of
the gene by using the denoised intensity values from the subimages.
7. Repeat steps 2 through 6 for the mismatch (MM) probe squares of the gene.
8. Repeat steps 2 through 7 with PM and MM squares of all remaining genes.
9. Create the CEL file by taking the 75th percentile value of each probe square, and
process the CEL file using Affymetrix software to arrive at the final expression
values of the genes.
The denoising methodology was coded in C and a C-MATLAB interface was used to
access MATLAB programs from [62]. The processing of all programs was carried out
using the high performance computing resources provided by Research Computing
Department at USF [63].

3.3

Numerical Validation using Simulated and Affymetrix Microarray
Data
In this section we present the results of the tests used to measure the performance

of our denoising methodology. Peak Signal-to-Noise Ratio (PSNR) is one of the
commonly adopted measure of performance for techniques used in denoising of natural
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images [64, 53]. PSNR measurement generally involves denoising an image that was
created by adding a known quantity of Gaussian noise to a clean image. The value
of PSNR, calculated in decibels, is inversely proportional to the noise that remains
after denoising, and hence a higher value represents better denoising. The PSNR is
calculated as follows.
P SN R = 20log10
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sk denotes the k th pixel intensity of the clean image, dk is the corresponding value of
the denoised image, and N denotes the total number of pixels. Clearly, a clean image
is essential in establishing the performance of a denoising methodology using PSNR.
Due to the unavailability of a clean microarray image, we first tested our methodology
on a simulated image as described below.

3.3.1

Testing Denoising Performance on a Simulated Image

Since our methodology separately denoises each subimage created for a gene, we
fabricated a clean dyadic subimage of size 32 × 32 pixels. As described earlier in
the example in Step 3 of Section 3.2.3, the simulated subimage consisted of 9 probe
squares. We also simulated another subimage with 16 probe squares (obtaining 28
X 28 pixels and repeating four rows and columns to get 32 X 32). Similar denoising
performance was noted in both subimages, and the one presented here is for the
16 probe square subimage. The pixel intensities within a probe square were kept
constant. Mimicking the actual values of a subimage from a real microarray data set,
different intensity values for the probe squares across the simulated subimage were
chosen. Two separate sets of noise having Poisson and Gaussian distributions were
added to the simulated subimage, and subsequently denoised using our methodology.
Poisson noise, proportional to the pixel intensity of the probe squares, and Gaussian

66

noise, with different values of the variance parameter for different trials, were added
to the clean image using functions available within the MATLAB software.
The PSNR values for different error combinations are presented in Table 3.1 and
3.2. PSNR in Table 3.1 was obtained by considering k in sk and dk as individual
pixel index, while in Table 3.2 k is a probe square index and sk and dk represent
the 75th percentile of the pixel intensities of the k th probe square. Different image
types that are considered in the tables (see column 1) are as follows: (1) noisy image,
where PSNR calculation is based on pixel values of the clean and noise added (without denoising) images, (2) denoised image without Poisson transformation, where
PSNR is calculated using clean and denoised images and the denoising is carried out
without including Gaussian transformation of the Poisson noise, and (3) denoised
image with Poisson transformation, where PSNR is calculated using clean and denoised images and denoising is done using the complete methodology, i.e., including
Gaussian transformation of the Poisson noise. The following observations are made

Table 3.1. PSNR value estimated by taking error, epsilon, as difference between individual values

∗

Parameter of the Poisson noise added is proportional to intensity of corresponding
probe square
from Tables 3.1 and 3.2. In both tables, the higher PSNR values for the denoised
images with/without using Poisson transformation indicate a significant improvement
compared to the PSNR values of the noisy images. According to the literature on
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Table 3.2. PSNR value estimated by taking error, , as difference between 75th percentile of probesquare

denoising studies ([64, 53]), the PSNR values obtained here can be considered high
indicating a desirable denoising performance. A comparison of the PSNR values obtained without and with Gaussian transformation of the Poisson noise (2nd and 3rd
rows of the numbers respectively), shows a significant difference, thus clearly establishing the importance of including the transformation strategy in our methodology.
In what follows, we present results from application of our methodology on a set of
Affymetrix microarray data.

3.3.2

Testing Denoising Performance on Affymetrix Microarray Data

Having established the performance of our methodology on a simulated data set,
we extended our testing on data sets obtained from Affymetrix GeneChip human
genome HG-U133 Plus 2.0 arrays, processed on HCT-116 colorectal cancer cell line
at the Microarray Core Facility of Moffitt Cancer Center and Research Institute.
Due to the unavailability of clean images we could not compute PSNR to measure
the extent of noise removal. Hence, we adopted a strategy of testing noise reduction
through coefficient of variation (CV) of the original and denoised data sets. The
premise of the strategy is that, multiple instances of a data set with random noise
are likely to have a higher CV compared to that from corresponding data sets from
which some of the noise has been removed. However, it may be noted that though a
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reduction of CV is indicative of noise removal, it cannot be directly translated into
the extent of noise removed.
An assessment of denoising performance should ideally be based on gene expression values obtained from before and after denoising. However, to obtain the gene
expression values, the data sets (pixel intensities) are processed using Affymetrix
GCOS or MAS5 software. These softwares perform data transformations, like background correction, before converting pixel intensities into gene expression values. As
a result, the gene expression values will reflect the impact of our denoising method
as well as that of the transformations performed in GCOS or MAS5. Thus, it would
be difficult to estimate the effect of our denoising methodology alone when gene expression values are used. Hence, instead, we used the pixel intensities. We conducted
two different denoising performance measurement tests as described below.

3.3.2.1

Analyzing CV of Probe Squares Across Multiple Scans of a Microarray

In this test we collected three different scans of a single chip resulting in data sets
containing same hybridization noise but different scanning noise. The data sets were
denoised individually using our methodology, and subsequently CEL files were created
by representing each probe square with a single value equal to the 75th percentile of
its pixel intensities. For each probe square, CV of its values across the three scans
was computed from the CEL file data. The above procedure for CV calculation for
each probe square was also repeated using the data sets prior to denoising (i.e., using
the original data). In order to assess denoising performance, we divided the range of
CV (0 to 1) into multiple subdivisions. We chose finer subdivisions near the lower
range of CV values and wider divisions towards the higher end, since a majority of the
probe squares had a relatively smaller CV. The number of probe squares under each
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Figure 3.3. Distribution of probe squares showing impact of denoising

CV range was counted for both original and denoised data sets and plotted as shown
in the top plot of Figure 3.3. The shift in the histogram of denoised probes (indicated
by dotted bars) towards the lower CV range (leftwards) indicates the reduction in
noise after denoising. The bottom plot of Figure 3.3 shows the difference between the
denoised and original number of probe squares under different CV ranges. A positive
rectangle for a CV range implies that the number of probe squares in the denoised
image is greater than the number of probe squares in the original image. The figure
shows four distinct zones of CV values: [0-0.07]; (0.07-0.12]; (0.12-0.16]; (0.16-1.0];
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we henceforth refer to these as zones 1, 2, 3, and 4 respectively. The following are
interpretations of the data observed in these zones.
1. Zone 1 shows a total increase of 42,289 probe squares in the denoised set.
Clearly, these probe squares had higher CV values (zones 2 through 4) in the
original set. This is indicative of noise reduction.
2. Zone 4, with highest CV values, shows that the denoised set has much less
number of probe squares (9,998) than in the original set, which indicates that
after denoising many probe squares in this zone have reduced their CV values
and thus migrated to the left (zones 3 through 1).
3. Probe distributions in zones 2 and 3 are resultant of the migrations described
for zones 1 and 4.
4. Zones 1 and 4 indicate a CV reduction for 52,287 probes. However, the total
number of probes that experienced a CV reduction is likely to be higher, since
it is difficult to assess the exact number. In perspective of the total number
of probes squares in a microarray (approximately one million), this number
(≥ 52, 287) might seem small. However, the bottom plot of Figure 3.3 shows
that a vast majority of the probe squares have CV lower than 0.24. Thus it can
be concluded that the original data had a small amount of noise, some of which
has been removed.
From the above, we can conclude that our methodology is capable of reducing noise
introduced during the scanning process. Tests performed on two other data sets
yielded similar results. However, as mentioned earlier, the extent of noise removal
could not be ascertained.
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s
Figure 3.4. Proportion of probe squares in various ranges of RCV
for Scan 1 data

3.3.2.2

Analyzing CV within Probe Squares of a Microarray

In order to assess performance of our methodology in removing noise introduced
during hybridization, we compared, between original and denoised data sets, the
variation across pixel values of each probe square in a data set obtained from a single
scan. The CV across each probe square s, was calculated from original and denoised
s
DAT files, which were used to obtain the percentage reduction in CV (RCV
)due to

denoising as,
(s)

s
RCV

=

(s)

CVorig − CVdenoi
(s)

CVorig

× 100

Figure 3.4 presents a pie-chart that shows the proportions of the probe squares in
s
values for Scan 1 data set. Data sets from scans 2 and 3 yielded
various ranges of RCV

very similar results. It is apparent from the figure that almost all probe squares
have had a high reduction in CV. However, due to the nature of the wavelet based
denoising approach, the reduction in CV values cannot be attributed completely to
the reduction in hybridization error. A better testing strategy would be to hybridize
multiple chips from a single sample, scan them to obtain the DAT files, and denoise
them separately. Comparing the CV of each probe square using data from the CEL
files of these multiple chips, in a manner similar to that presented above for the test
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using multiple scans, will give us a better estimate of hybridization noise reduction.
Due to the immediate unavailability of such a dataset, we were unable to perform the
stated testing strategy.

3.4

Conclusions
A novel multiresolution analysis based methodology, using a dual-tree complex

wavelet transform and bivariate shrinkage thresholding, for removing hybridization
and scanning noise from microarray data is presented. Two specific microarray data
features that are not conducive to wavelet based denoising are identified, for which
specific data transformation strategies are developed. The aforementioned features
are: presence of excessive number of edges in microarray images, and non-Gaussian
(Poisson) distribution of the hybridization noise. The strategies involve creation and
denoising of separate subimages for each gene (instead of the complete microarray
image), and Gaussian transformation of the Poisson noise prior to denoising. A
comprehensive approach to denoising microarray data, as presented in here, is not
available in the open literature. We believe that our approach to removing noise from
microarrays will increase the reliability of gene expression values for use in disease
diagnosis and treatment planning.
Testing the performance of any image denoising methodology requires noisy image
along with its clean base image. Since it is not possible to have a clean base image for
a microarray, testing of our methodology was first carried out using data simulated
to mimic microarray probes. When noise was introduced to the simulated data,
our methodology was able to remove them to a significant extent as evidenced by
PSNR (peak signal to noise ratio) values. The testing was then continued with image
data sets obtained from Affymetrix microarrays processed on colorectal cancer cell
samples. Due to unavailability of clean base image, coefficient of variation (CV) based
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comparison strategies were developed to obtain measures of denoising performance.
A considerable extent of quality improvement was noticed for the tested Affymetrix
data sets.
Though our methodology is capable of identifying hybridization and scanning
noise with the use of a single chip, identification of sample preparation noise still
remains an open challenge. The reduction of the portion of sample preparation noise
which is due to randomness in amplification rate, is dependent on the techniques
used to control or maintain a constant rate. This is considered beyond the scope of
our current research. However, it is possible to extend our methodology to identify
the portion of sample preparation noise which is due to the probabilistic nature of
amplification. This could involve creating subimages with probe squares of the same
gene from multiple chips. Since the distribution of this noise is also Poisson, like
that of hybridization, probe squares from the same location on the multiple chips
will have Poisson noise of magnitude equal to the sum of the two individual Poisson
noise types. We believe, therefore, that the application of our current methodology
will offer desirable performance. However, since the sample preparation noise is only
a small portion of the total noise, the requirement of multiple chips may not be
economically justified, except in cases where multiple chips are naturally involved in
the experiment.
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CHAPTER 4
ANALYTICAL PROCESSING OF CHROMATOGRAMS

4.1

Introduction
Proteome, the set of proteins translated by the genome, is the main component

that drives the metabolic activities in a cell. Hence, the proteome is anticipated to
hold the key to the pathway of diseases like cancer and therefore play an important
role in cancer diagnosis and treatment. However, application of this theory into
practice requires identification and quantification of the proteins produced in the cell,
which is a challenging task because of the complexity of the proteome. While an
organism has a constant genome, its proteome varies from cell to cell. Proteins are
produced or translated by genes that are active or expressed, and different genes are
expressed in different parts of the body. The 35,000 genes of the human genome
are estimated to translate more that ten times as many proteins, where the type
and quantity of protein produced is based on the coded information contained in the
gene. In extreme cases, an individual gene could have a coding capacity of about
1000 proteins [65]. Due to variations in the translation process, the same gene could
produce different forms of the protein (protein isoforms) that differ in their function
of metabolic activities [66]. Further, the structure of the protein could change after
production (post-translational modifications (PTM)) [67], hence creating proteins
with functions that are different from the original. This complex structure of the
proteome creates challenges in identifying and quantifying proteins produced in a
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cell, and thus several proteins and its function are still unknown. Identifying protein
biomarkers, i.e., the sets and quantity of proteins present in the cell only during a
disease state, will help in diagnosis and further in drug discovery for the respective
disease. Since early diagnosis of cancer lead to better chances of survival, identifying
protein biomarkers related to early stages of cancer is essential.
Advancements in the area of protein profiling, a technique for detecting proteins
in tissue, blood, or urine samples [68, 69], has led to the identification of a number of
protein biomarkers. However, thus far, very few have been identified, e.g., in ovarian
cancer, CA125 is the only clinically used biomarker for diagnosis with a sensitivity of
only 50% for early stages of cancer [70, 71]. Other biomarkers that have been identified lack the required specificity and hence cannot be applied to population-wide
screening. Along with the complex structure of the proteome, the current lack of
efficient biomarkers can be attributed to challenges such as chemical separation of
the proteins [72]. The separation, generated using inherent difference in property of
proteins, is required for identifying and measuring the quantify of each protein. Incomplete separation causes low quantity (i.e., low abundance) proteins to be masked
by those in high abundance and hence several significant proteins might yet remain
unidentified [73]. Another significant challenge is during the analytical quantification of protein values from the plots, called chromatograms, generated during protein
profiling. Chromatogram is a visual representation of the protein separation, where,
the measure of certain chemical components in a sample that are reflective of the
separated proteins are plotted. In this research, we develop a methodology for addressing challenges in protein identification and quantification from chromatogram
data. Before giving a detailed description of a chromatogram and discussing the
research problem, we briefly explain some of the protein profiling techniques.
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Most protein profiling techniques, e.g., 2-dimensional electrophoresis (2DE), matrix assisted laser desorption and ionization (MALDI), and surface-enhanced laser
desorption and ionization (SELDI), use protein characteristics like hydrophobicity,
ionization mass, and electrophoresis [67, 74, 75] to separate proteins. However, small
differences in hydrophobicity or large ionization mass between different proteins hinders protein separation [67]. In this research, we develop a methodology to process
chromatograms generated by Beckman Coulter ProteomeLab Protein Fractionation-2
Dimension (PF2D). PF2D follows a two dimensional approach, where, separation in
the first dimension is based on the varying isoelectric point (pI) of proteins and the
sample is separated into fractions based on pH. In the second dimension the proteins
in the fractions are further separated using the property of hydrophobicity ([76]). This
approach is found to account, to some extent, for post-translational modifications of
proteins and to improve reproducibility of protein detection, which are weaknesses
of the other profiling techniques [67, 76]. Also, the increased capacity of PF2D to
separate proteins provides an additional leverage in analyzing low abundance proteins, which otherwise would have been masked by high abundance proteins. The
use of PF2D in proteomics has been well-established technically [77, 78, 79, 76, 80],
and has been shown to be promising for biomarker research [81, 82]. However, the
task of quantitative processing of the chromatograms is complicated because, while
high abundance proteins can be easily quantified from these plots, identifying and
quantifying low abundance proteins is a challenge. The rest of this chapter is structured as follows: description of the PF2D chromatogram, quantitative challenges in
its processing, and current literature are discussed in Section 4.2; the methodology for
quantitative processing is presented in Section 4.3; and the results of the methodology
are presented in Section 4.4.
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4.2

Description of PF2D Chromatograms and Quantitative Challenges
A sample chromatogram output generated from the PF2D second dimensional

separation, that was applied on a fraction from first dimension separation, is presented in Figure 4.1. Approximately 17 such fractions, separated based on pH, are
obtained for one blood or urine sample, however, the number can be varied based on
requirements. During the second dimensional separation, proteins in the fractions are
detected by the amount of UV absorbance and as in Figure 4.1 the absorbance unit
(AU) is plotted against retention time ([76]). Interpreting the plot, the spikes or peaks
are indicative of the presence of proteins, and based on the effectiveness of separation,
each peak represents one or more proteins. The area underneath the peak is equivalent to the amount of the protein present in the sample. Analytical processing of the
chromatogram involves identifying the presence and location of peaks, and estimating
the area of each peak. Further, by comparing equivalent peaks across samples, peaks
that distinguish cancer cases from controls (potential biomarkers) can be obtained.
To identify the protein content of the required peaks, the corresponding portion of
the fraction can be chemically analyzed. This feature of PF2D, which allows future
analysis of fractions of interest, is an advantage over other protein profiling techniques
([76, 67]). One of the significant reasons for the lack of effective protein biomarkers
can be attributed to the challenges in the analytical processing of chromatograms.
We explain below the steps and challenges in PF2D chromatogram processing.
1. Baseline Correction: During the generation of the chromatogram, ideally, the
presence of proteins should reflect as a positive value and absence a value zero.
However, due to difficulties in setting the correct baseline, the signal drifts to
either side of zero as can be seen in Figure 4.1. Hence, the first task is to identify
the baseline for the generated signal.
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Figure 4.1. Sample PF2D signal
2. Peak Identification: Figure 4.2 presents an enlarged image of a section of Figure
4.1. Note that, though we can visually identify peaks in the signal, it is a
tedious and manually infeasible task as each sample contains thousands of peaks
and obtaining biomarkers requires analyzing hundreds of samples. Therefore,
developing a methodology for mathematical identification of peaks is essential.
While large peaks, like B and D in Figure 4.2, can be easily identified using
mathematical tools, it is a challenging task to differentiate smaller valid peaks,
like C and E, from noise. Since most proteins are present in small quantities in
blood and urine, successful identification of small peaks would be essential for
detection of potential low abundance biomarker proteins [83].
3. Intensity Quantification: Obtaining biomarkers involves identifying proteins
that are produced in distinguishably different quantities across cases and controls. Hence, the third step involves quantifying the area of each peak which is
equivalent to the quantity of the proteins represented by the peak. Estimating
the area is a challenging task due to the presence of overlapping peaks, e.g.,
A and B in Figure 4.2, which are caused by incomplete separation of proteins.
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Figure 4.2. Peak identification and intensity quantification
Since each peak is most likely representative of a set of proteins rather than
an individual protein, it might seem fair to group peaks A and B and estimate
the area under the combined peaks, which is a relatively easier task. However,
this will be undesirable for identifying distinguishable proteins across cases and
controls, the reason for which can be explained as follows. As seen in Figure 4.2,
most of the small peaks overlap with the larger peaks. Hence, if these peaks are
grouped, when comparing peaks across cases and controls, the high value of the
large peaks will mask any significant difference that exists across the smaller
peaks. Hence, developing an algorithm that identifies and quantifies all peaks
is essential.
4. Peak Alignment: Ideally, identical peaks, i.e., those that represent the same set
of proteins across samples, should be aligned in time since they are detected
based on protein properties. However, as highlighted in Figure 4.3, due to
chemical causes ([79]), there is a horizontal shift in the occurrence of peaks in
sample 1 when compared to identical peaks in sample 2. Hence, for comparison
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Figure 4.3. Horizontal shift of peaks
across cases and controls, identical peaks across all samples need to be aligned
along x-axis (time).
Currently, 32 Karat is the software that is mainly used for quantitative processing of PF2D chromatograms ([76]). The drawback of the software is that it is not
completely automatic but manual, like setting targets for aligning peaks and peak
identification, and multiple sample alignments is also not possible. While mathematical methodologies for processing of PF2D chromatograms are limited, literature
presents methodologies for other protein profiling techniques, where, the quantitative
steps involved in processing are similar to that explained above. Most commonly
used protein profiling techniques are mass spectrometry (MS) based, where the proteins are detected based on mass-to-charge ratio (m/z) unlike pH or hydrophobicity
in PF2D. The spectral signals generated by MS techniques contain the number of
ions, indicating intensity of proteins, versus the corresponding m/z values. Current
methodologies for quantitative processing of SELDI and MALDI based MS signals
have been reviewed in [84] and [85], respectively, which can be summarized as follows. Methodologies for baseline correction include dividing the signal into windows
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and scaling to local minima in each window ([86, 87]), using a global moving average
([88]), or linear interpolation ([89, 90, 91]). Some methodologies smooth the signal,
to remove noise before peak identification technique, by applying a moving average
filter ([92, 93]) or a Gaussian filter ([90, 94]). The crest of the peak is identified as the
local maxima and considered as a valid peak if signal-to-noise ratio (SNR) is greater
than a user-defined threshold ([90, 93, 94, 95, 96]), or in addition, also use a baseline
threshold and ignore all peaks below this value ([88]). SNR of a peak is usually obtained as the local average divided by the local standard deviation. Other techniques
of peak identification, along with SNR, use a baseline value to identify beginning and
end of peaks and apply a threshold for peak width ([97]), or estimate slopes and use a
threshold for both sides of the crest to determine a valid peak ([89]). While the above
techniques are successful in identifying high abundance peaks, identification of low
abundance peaks is subject to surrounding signal region thus creating inconsistencies
in results. Since noise varies along the signal, small peaks in the vicinity of little or
no noise or in the presence of large peaks might have a low SNR value, even equal or
lower than that of a noise peak in other parts of the signal. Hence, it is not possible
to set an optimal threshold. Methodologies in [98, 99, 95, 96, 86] use wavelet based
signal processing tools (extracting signal at multiple frequencies/scales) to identify
peaks.
The methods presented in literature have been successful in automatically identifying certain peaks, and as presented by [84] and [85], based on identification of
known proteins, the method in [98] performs better than other techniques. However,
the current methods do not include techniques for identification of small peaks or
overlapping peaks. Most methods use thresholds in differentiating noise from valid
peaks, and it has been seen that low thresholds increase false discovery rate, while
high thresholds miss several valid peaks. In this research, our main focus is in identifi82

cation and quantification of small peaks and overlapping peaks. Since blood circulates
throughout the body, it contains proteins from all parts of the body. There are about
500,000 proteins produced in the human body most of which are present in small
amounts in blood and urine, and several of which are yet to be discovered. Therefore,
identification of the small peaks that represent low abundance proteins is essential
for obtaining potential biomarker proteins [83]. Also, due to incomplete protein separation, most of the small peaks overlap with and occur on shoulder of large peaks.
If these overlaps are not separated, during the process of identifying peaks that distinguish cancer cases from controls, any significant difference in the small proteins
will be masked by the larger proteins. Hence, in this research, we develop continuous
wavelet transforms based methods to address challenges with peak identification and
quantification especially those that have low abundance or overlap.
Peak alignment is a task encountered in several areas in biochemistry and the
literature presents considerable number of methods based on time warp or sequence
alignment, and several of which perform peak alignment prior to peak detection. The
authors in [100] present a method for peak alignment of PF2D chromatogram. The
method has been derived from dynamic time warp based on dynamic programming
that was originally developed for speech recognition, and has been used for alignment
of chromatograms in other biochemistry techniques [101, 102, 48]. In such methods,
the signal is usually divided into number of sections and each section is stretched or
shortened by shifting its ends within a slack parameter, and interpolating the signal points in between. The shift that provides the best correlation coefficient with
the target signal is retained. Such a method will change the profile of the peak and
therefore its area, which is not suitable in our application as we are interested in identifying proteins that have distinguishing quantities (areas) across cases and controls
(biomarkers). Other similar methods based on techniques of time warp are presented
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in [103, 104]. A scale-space representation, similar in concept to a wavelet function,
but using a Gaussian function and for peak alignment of multiple spectra is presented
in [105]. By obtaining Dirac components as sum of weighted distance between peaks
from all spectra (samples) and convolving with the Gaussian function, the common
peak location across spectra is obtained as the local maxima of the resulting function. However, its performance with overlapping peaks and low abundant peaks is
dependent on setting appropriate coefficient weights derived from prior knowledge of
biology, which is not feasible to obtain in our application. In this research, we first
perform the peak identification and quantification followed by alignment of the identified peaks by using a simple model based on mixed integer-nonlinear programming.
We follow such a sequence as individual peak quantification is essential for obtaining
biomarkers and also to avoid any changes in profile, especially in low abundant peaks,
that might result if alignment is conducted first.

4.3

Methodology for Quantitative Processing of PF2D Chromatograms
In this research, we developed a mathematical model using continuous wavelet

transforms for baseline correction, peak identification, and quantification, and an
optimization model for peak alignment. In what follows, we briefly discuss wavelet
transforms and explain in detail the methodologies for the quantitative processing.

4.3.1

Continuous Wavelet Transforms for Baseline Correction, and Peak
Identification and Quantification

Wavelet is a short wave, and note that, in Chapter 3, we briefly discussed discrete
wavelet transforms for removing noise from microarray images. For chromatogram
processing, we use continuous wavelet transforms (CWT), defined as the convolution
of the normalized form of a function ψ(t), called the mother wavelet, with the data
84

signal x(t) to obtain wavelet transforms T (a, b) at scale a and translation b ([106]).
We will discuss later in this section the advantage of using continuous over discrete
wavelet transforms for chromatogram processing. The mathematical representation
of CWT is written as
!

t−b
1 Z∞
x(t)ψ
dt
T (a, b) = √
a −∞
a

(4.1)

Scale can be referred to as the stretched/squeezed form of a wavelet and translation
as the position of the center of the wavelet on the x-axis. By varying the values of a,
the signal can be decomposed or represented at different frequencies and the value of
the transform at varying b can be obtained. In this research, we use the Mexican hat
wavelet function (Figure 4.4) which is written as ([106])

Figure 4.4. Mexican hat wavelet
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(4.2)

By using such a peak shaped wavelet function, identification of peaks in a chromatogram can be achieved by utilizing values of T (a, b) which is explained as follows.
As an illustration of scaling and translation, we depict in Figure 4.5 a wavelet at fixed
translation b and at three scales a1 , a2 , and a3 , (a1 < a2 < a3 ), and in Figure 4.6
a wavelet at a fixed scale and three translations b1 , b2 , and b3 .
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Visually, it can be

Figure 4.5. A wavelet at a fixed translation and at three different scales

Figure 4.6. A wavelet at a fixed scale and three different translations
seen that the wavelet at scale a2 and translation b2 is the best match for representing
peak A, and mathematically it will be seen that T (a2 , b2 ) will attain the maximum
value among all a and all b in the neighborhood of the peak. We can explain this
mathematical behavior by considering the positive or negative yield of the convolution
(x(t)ψ



t−b
a



) in Equation 4.1 using Figure 4.7, as follows. For a wavelet with fixed a

and b, Figure 4.7 indicates with a ‘+’ or ‘-’ sign the positive or negative value resulting
from the convolution at different time segments (t) marked by the vertical lines along
the x-axis. The time segments where the wavelet and signal are both positive or both
negative result in a positive value for the convolution, and yields a negative value
when they are of opposite signs ([106]). Hence, in our example in Figures 4.5 and 4.6,
considering the different values of a and b it can be seen that T (a2 , b2 ) will provide
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Figure 4.7. Positive and negative contributions of convolution of the wavelet with a
signal
the maximum value. Sample values of T (a, b), also commonly referred to as wavelet
coefficients, at five scales and all translations for the length of the signal are plotted
in Figure 4.8. As seen in the Figure, the use of CWT provides continuous translations
thus generating continuous coefficients, which also appear as peaks with the use of
suitable wavelet functions like the Mexican hat used here. Hence, the local maxima
of coefficients at each scale represents the presence of peaks, and for each peak k, the
best match scale (aˆk ) and translation (bˆk ) are obtained as the scale and translation of
the local maxima (Tk (aˆk , bˆk )) where bk is in the neighborhood of k. From the set of
identified local maxima, we further develop techniques to differentiate between noise
and actual peak, which is explained later in this section. Further, since the baseline
of the signal changes slowly thus making it monotonic around a peak, the convolution
with a compact symmetric wavelet (e.g., Mexican hat) provides an automatic baseline
correction ([98]). Notice that the baseline correction is visible in Figure 4.8, where,
the coefficients take a zero baseline while the original signal had a baseline around
1500. Note that, in case of clear peaks, i.e., no overlaps, the value of Tk (aˆk , bˆk ) (see
Equation 4.1) is proportional to the area underneath the corresponding signal peak
k, and the location of the crest of k is bˆk . However, in case of overlap peaks, neither
Tk (aˆk , bˆk ) or bˆk will give an estimate of the peak quantity or location, respectively.
Therefore, in this research, we also develop a methodology for quantifying overlapping
peaks.
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Figure 4.8. Sample plot of wavelet coefficients
Using the above knowledge of CWT, we describe below the steps for identification
and quantification of peaks, including techniques for small peaks and overlapping
peaks.
1. Obtain CWT coefficients T (a, b), (∀a, ∀b). The resulting T is a two dimensional
matrix of size M xN , where, M is the number of scales and N is the length of
the signal.
2. Using slopes, identify local maxima at each scale to obtain a matrix P of size
M xN . If a local maxima is found at T (a, b), P (a, b) = T (a, b) else P (a, b) = 0.
3. Link local maxima (non-zero P (a, b)’s) across scales: As discussed earlier, the
optimal scale â for a peak corresponds to the maximum value across scales, i.e,
P (â, b) = maxa P (a, b). However, for any peak in the signal, its local maxima
across scales does not occur at the same translation, i.e., if Pk (1k , b1k ) and
Pk (2k , b2k ) are the local maxima corresponding to a peak k at scales 1 and 2,
respectively, b1k 6= b2k for most peaks. Therefore, to identify âk , the non-zero
values of P (a, b) across all scales that correspond to peak k need to be first
linked. To achieve this, beginning at the lowest scale (we start with 2 since
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scale 1 mostly represents noise), perform the following steps at each scale. Note
that, the concept of linking local maxima is similar to obtaining ridges in [98],
however, there are changes in the procedure that we adopt.
(a) For each (ā, b̄) where P (ā, b̄) 6= 0, using a window size w find a matrix
index (a, b), such that, (a ∈ 1 : ā − 1, b ∈ b̄ − w : b̄ + w) and P (a, b) 6= 0,
i.e, find a local maxima in any of the previous scales in the neighborhood
b̄ ± w. The search is done in more than one previous scale, since, based on
features of the signal, the local maxima might not occur at all scales. Note
that, instead of setting a fixed value for w like in the literature, we estimate
peak dependent value which is explained at the end of this section.
(b) If found, suppose at only one index (ā − 1, b̄ − 4), i.e., P (ā − 1, b̄ − 4) 6= 0,
then set P (ā, b̄ − 4) = P (ā, b̄) and P (ā, b̄) = 0, i.e, shift the location of the
local maxima at scale ā to align with that of the previous scales indicating
that they belong to the same peak. If found in more than one index in the
neighborhood b̄ ± w, move it to the nearest location.
(c) If not found, i.e., P (a, b) = 0 ∀(a ∈ 1 : ā − 1, b ∈ b̄ − w : b̄ + w), then retain
the value of P (ā, b̄), thus indicating that it is a new peak.
4. Location of peaks: Each non-zero column b̄ in the modified P indicates the presence of a signal peak. For peak k, set the optimal scale as aˆk where, Pk (aˆk , b¯k ) =
maxak Pk (ak , b¯k ), and for now, consider the quantity of k as Q(k) = Pk (aˆk , b¯k ).
Set the location of the crest of k as L(k) = b¯k , thus corresponding to the location
of the local maxima at the lowest scale, the reason for which can be explained
as follows. For clear non-overlapping peaks, the location will be equal to the
original best fit bˆk in T , i.e., corresponding to Tk (aˆk , bˆk ) = Pk (aˆk , b¯k ). However,
in case of overlapping peaks, column bˆk will be skewed away from the location of
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the peak crest. Now, consider the translation of the wavelet at a point b1 that
corresponds to the crest of a peak in the signal x(t). At lower scales where the
width of the wavelet is very small, it is most likely that the wavelet is completely
contained within the region of the signal peak for translations b1 ± n for a small
n. Hence, the signs of the convolution along different segments of the wavelet
(recollect Figure 4.7) will be the same at all b1 ±n, thus resulting in a maximum
value of T at a translation where x(t) would have the maximum profile, i.e.,
at b1. Therefore, the location of the local maxima at the lower scales is most
likely to correspond to the crest or very close to the crest of the signal peak.
See Figure 4.9, that contains a sample plot of T (a, b), x(t) (signal), and P (a, b),
for a better understanding of the relationship between the variables. Note that,
the figure shows only 10 scales for ease of illustration. Due to the overlapped
peaks, the location of Tk (aˆk , bˆk ) is skewed away from the peak crest, however,
the location corresponding to the translation at the lowest scale (b¯k ) provides a
better estimate.

Figure 4.9. Location of peaks
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5. Identification of valid peaks: For each peak k perform the following steps.
(a) Estimate the width (W (k)) of the peak formed by the wavelet coefficients
at scale aˆk by searching around bˆk . Identify the highest scale at which the
peak is recorded, H(k), as the highest non-zero scale in Pk (ak , b¯k ).
(b) Retain k as a valid peak by setting thresholds for W (k),

Q(k)
W (k)

and H(k).

6. Quantification of overlapping peaks: Peak quantity is obtained by utilizing
the knowledge of the positive and negative contributions to T arising from
the convolution (refer to Figure 4.7 for the convolution contributions), and
is explained as follows. Notice that, for any clear peak k, while bˆk (i.e., the
translation that provides the maximum transform Tk (aˆk , bˆk )) is equivalent to
the location of the peak crest, Tk (aˆk , bk ) ≤ 0 when bk corresponds to the
peak troughs. Let bk = sk (a) and bk = ek (a) denote two translations (referring to (s)tart and (e)nd) at scale a in the neighborhood of peak k such that,
sk (a) < ek (a) and Tk (ak , sk (a)) ≤ 0, Tk (ak , sk (a) + 1) > 0, Tk (ak , ek (a)) ≤ 0,
and Tk (ak , ek (a) − 1) > 0. Now consider two peaks i and j that overlap,
and since they are almost always not of the same frequency, âi 6= aˆj , and
let âi < aˆj . Due to the mathematical form of the convolution, the functions
Ti (âi , si (â) : bˆi : ei (â)) and Tj (aˆj , sj (â) : bˆj : ej (â)) will be such that, there will be
some amount of overlap of the regions si (â) : ei (â) and sj (â) : ej (â). The overlaps could either be complete, i.e, sj (â) ≤ si (â) ≤ ei (â) ≤ ej (â) (scenario 1), or
partial, i.e, either sj (â) ≤ si (â) ≤ ej (â) ≤ ei (â) or si (â) ≤ sj (â) ≤ ei (â) ≤ ej (â)
(scenario 2). Scenario 1 will most likely occur in cases when the smaller peak i is
a low abundant peak occurring on the shoulder of a large peak, e.g., as in Figure
4.10, which presents the signal and its wavelet coefficients T (a, b) at 25 scales.
Utilizing the above knowledge and identifying overlaps of scenario 1, estimate
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Figure 4.10. Estimating area of overlapping peaks under Scenario 1

Figure 4.11. Estimating area of overlapping peaks under Scenario 2
Q(i) = Ti (âi , bˆi ) and Q(j) = Tj (aˆj , bˆj ) − Ti (âi , bˆi ). Scenario 2 represents incomplete separation of two protein sets, where, the overlap will cause the coefficient
to be maximum at a scale larger than the actual scale of the larger peak j (e.g.,
see Figure 4.11). Therefore, by identifying overlaps of scenario 2, and by searching through scales below aˆj , obtain a scale ā where sj (ā) < ej (ā) < si (ā) < ei (ā)
or si (ā) < ei (ā) < sj (ā) < ej (ā). Identify the translation of the local maxima
at a¯j as b¯j . Now, quantify the peaks as Q(i) = Ti (âi , bˆi ) and Q(j) = Tj (a¯j , b¯j )
(see Figure 4.11).
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Note that, the algorithm presented in the above steps identifies low abundant
peaks as well. For example, unlike use of signal-to-noise ratio (SNR) as in most
methods in the literature, the thresholds for peak identification used in this research
(W (k) and

Q(k)
W (k)

and H(k)) are only dependent on the peak under review and not

on the neighborhood signal. Since noise varies along sections of the signal, using
the characteristics of the peak alone helps obtain a better identification. Also, for
each peak k at each scale a, the search window w for linking local maxima is set as
w = sk (a) : ek (a), where the translations bk = sk (a) and bk = ek (a) are as explained
in Step 6 of the algorithm. Notice that, as a increases, ek (a) − sk (a) increases or
remains the same and sk (a) ≤ sk (a − 1) ≤ ek (a − 1) ≤ ek (a)). Therefore, instead
of setting a constant window size, determining the value based on the feature of
the peak, as discussed above, provides a better search criteria. While incomplete
chemical separation of proteins created overlapping peaks, using wavelet features to
identify and quantify the value of each of these overlapping peaks provides as much
protein separation as possible. Such separation allows for better identification of small
significant biomarker peaks, where otherwise, the non-separation would have caused
the large peaks to mask significant differences across small peaks.

4.3.2

Optimization Model for Peak Alignment

Alignment of peaks is achieved by developing an optimization algorithm. The
objective of the algorithm is to minimize the magnitude distance between two signals,
since misaligned peaks are likely to have more magnitude. Note that, in the context
of peak alignment, a signal is an array whose length equals the length of the original
chromatogram. The array elements take value equal to peak intensity if its array
index corresponds to location of identified peak (obtained using Q and L from Section
4.3.1), and takes a zero value at all other index. Distance is estimated as the sum of
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magnitude difference between elements of the two signals. The optimization model
developed for peak alignment is as follows. Let A and B be two signals, where the
objective is to align B against A, i.e., for every peak in A we need to find a matching
peak from B. Let Bm = AlignedB. The optimization model for the alignment is
formulated as follows.

Objective : M inimize

X

|A(x) − Bm (x)| +

x

Bm (x) =

X

θ(y)

y

X

B(y) ∗ β(y, x)

∀(x)

(4.3)

X

β(y, x) ≤ 1

∀(y)

(4.4)

β(y, x) ≤ 1

∀(x)

(4.5)

∀(x, ∀(j < x))

(4.6)

y

x

X
y

X
y

β(y, x)y −

X
y

X

β(y, j)y

X

β(y, x) ≥ 0

y

B(y) ∗ β(y, x) + θ(y) = B(y)

∀(y)

(4.7)

∀|y − x| > α,

(4.8)

x

β(y, x) = 0

where α= maximum possible shif t on x − axis(time − axis)
β(y, x)  {0, 1}

∀(y, ∀(x))

Bm (x)  R

∀(x)

θ(y)  R

∀(y)
(4.9)

The objective function minimizes ‘distance + unmatched’, where, ‘distance’ equals
the sum of difference between aligned peak intensities and ‘unmatched’ equals sum
of peak intensities in B(y) that did not find a matching peak in A(x). Constraint 4.3
tracks peak shifts by using binary variables, Constraints 4.4 and 4.5 avoid duplication
of peaks, Constraint 4.6 ensures that the sequential order of the peaks is maintained,
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Constraint 4.7 keeps track of peaks in B(x) that did not find a matching peak in A(x),
and Constraint 4.8 places a bound on the peak shift. Since peaks were expressed over
pH scale, the shift of peaks is limited to a range of neighboring pH and hence search
beyond the range is not required.

4.3.2.1

Transformation from Nonlinear to Linear

Note that, constraint 4.6 contains a nonlinear term. Since solving a nonlinear
model is much more difficult than a linear model, for computational efficiency, we
linearize constraint 4.6 as follows.

X

β(y, x) = γ(x)

∀(x)

(4.10)

δ(x) + γ(x) = 1

∀(x)

(4.11)

∀(x, ∀(j < x))

(4.12)

y

X

β(y, x) ∗ y −

y

X

β(y, j) ∗ y + δ(x) ∗ 100000 ≥ 0

y

δ(x)  {0, 1}

∀(x)

γ(x)  {0, 1}

∀(x)

Hence the above constraints will replace constraint 4.6.

4.3.2.2

Heuristics to Minimize Execution Time of Optimization Algorithm

The optimization algorithm described above for peak alignment was solved using
CPLEX optimization solver. For a pair of data signals, each with length 150 peaks,
the number of constraints will equal 30,225, and will increase to 97,950 for a length
of 300 peaks. The average signal length for a sample can be approximately 2250
peaks, making the problem very complex which can take forever to solve. Therefore,
we developed a heuristic approach to minimize the execution time which can be
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described as follows. Note that, for any given peak, the distance of shift is limited
due to its occurrence based on chemical property. Therefore we adopt the following
two step procedure of breaking down the signal into multiple smaller fragments:
1. Every sample has a small set of common high abundance proteins. Therefore, in
the first step, we consider a signal as an array of high abundance proteins only.
The optimization algorithm is applied to align these high abundance proteins
across two samples.
2. The point of alignments in step 1 is used as a breakpoint, to divide the entire
data set into multiple smaller signal fragments. Each signal fragment will consist
of an array of a small number of peaks. Therefore, in step 2, the algorithm is
applied on each set of signal fragment separately, and the peaks within each
fragment are aligned.

4.4

Results and Discussion
Our algorithm was tested on PF2D chromatograms obtained on urine samples of

ovarian cancer patients. The samples were obtained as part of the Tampa Bay Ovarian
Cancer Coalition (TBOCC)- a population-based study conducted by a team from
Moffitt Cancer Center and Research Institute, Tampa. The study is being performed
in the Tampa Bay metropolitan region of the State of Florida, where about 400 blood
and urine samples will be prospectively obtained from ovarian cancer patients and
also from a matching control. The cancer cases and controls are matched based on
demographics and risk factors like age, menopausal status, and race. This study, to
our knowledge, is the largest prospective collection of preoperative population-based
samples in the US.
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4.4.1

Peak Detection

For comparison of peak detection capacity, peaks in PF2D chromatograms were
identified using our algorithm and MassSpecWavelet ([98]), which is a peak detection method also based on complex wavelet transforms. Note that, MassSpecWavelet
was originally developed for SELDI-TOF mass spectrometry based spectrums, whose
protein separation procedure differs from that of PF2D as was explained earlier
in Section 4.2, however, with similar challenges in protein identification. We use
MassSpecWavelet for comparison as it has been shown to perform comparatively
better that the other algorithms ([85]) for peak identification. MassSpecWavelet differentiates between noise and valid peak based on two main thresholds, signal-to-noise
ratio (SNR) and amplitude of the local maxima of the peak. The SNR is estimated as
the ratio of local maxima to the local noise level, where, the noise level within a local
window size around the peak is estimated as the 95th percentile of the coefficients
at the first scale. Since MassSpecWavelet was developed for MS spectrums, we also
compare the peak detection capacity of the two algorithms on MS spectrums. We
present below, the comparison of results on PF2D chromatograms followed by MS
spectrums. Note that, all visual verifications mentioned below were based on expert
opinion, biochemists and oncologists.

4.4.1.1

Comparison of Peak Identification on PF2D Chromatograms

The thresholds in MassSpecWavelet and our algorithm were varied to obtain different number of peak selections, and the ensuing results with approximately same
number of selections in both algorithms were compared. While large peaks are identified in both algorithms, it was found that our algorithm performs better in identification of small peaks and overlapping peaks. A sample result is presented by considering
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Figure 4.12. Peak identification on section of chromatogram with several peaks
two sections of the same chromatogram, one with several valid peaks (Figure 4.12)
and the other with lot of noise (Figure 4.13). The blue lines indicate location of peaks
identified by our algorithm and red lines by MassSpecWavelet, where the number of
peaks identified are 145 and 142, respectively. Notice that, the section of the chromatogram shown in Figure 4.12 contains several small peaks and overlapping peaks,
and as circled, several of which are not identified by MassSpecWavelet. Moreover,
MassSpecWavelet identifies several false peaks in the tail end of the chromatogram
that usually has just a few valid peaks (Figure 4.13) and also misses some valid peaks,
which is more clearly seen in the enlarged portion between data points 6500 to 7100.
Note that, the false detection of peaks by our algorithm is much lesser as can be
seen in the Figure.

Though the chemical content of the small circled peaks, that

were missed by MassSpecWavelet in Figure 4.12, is not confirmed, it may be noted
that, such automatic identification of all peak like appearances is essential, the reason
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Figure 4.13. Peak identification on section of chromatogram with high noise
for which can be explained as follows. Since there are about 500,000 proteins most
of which are present in small amounts in urine and blood, obtaining the undiscovered small biomarker proteins requires identification of peaks that distinguish cancer
cases from controls. The vast number of small peaks makes it impossible to manually identify distinguishing peaks, and moreover the distinguishing characteristics
might be present in the form of a pattern or set, rather than individual peaks, hidden
from the naked eye. Hence, the identification of distinguishing peaks requires the use
of a mathematical model, and therefore, an automatic algorithm that identifies the
location and quantifies the area of all peak like appearances.
In order to test the capacity of identification of small and overlapping peaks by
MassSpecWavelet, the thresholds of peak detection were further lowered. As can be
seen in Figures 4.14 and 4.15, where the thresholds in MassSpecWavelet have been re-

99

Figure 4.14. Sample results of peak identification: Increasing peaks selected by
MassSpecWavelet to 172
duced to increase the number of peaks to 172 and 202, respectively, MassSpecWavelet
again misses the small and overlapping peaks.

4.4.1.2

Comparison of Peak Identification on MS Spectrum

Both algorithm (ours and MassSpecWavelet) were applied on MALDI TOF mass
spectrometry (MS) based Aurum data ([107] publicly available at https: // proteomecommons. org/). The advantage of using Aurum data is that it provides
the list of know valid peaks. Hence, we estimated the peak detection sensitivity of
both algorithms, and compared sensitivities corresponding to thresholds that provide
equivalent number of identified peaks in both algorithms. The number of peaks and
sensitivity results are presented in Table 4.1. For our algorithm, all thresholds were
kept constant except for

Q(k)
,
W (k)

which was varied to identify different number of peaks.
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Figure 4.15. Sample results of peak identification: Increasing peaks selected by
MassSpecWavelet to 202
In the Table, rows 1 to 3 present results where MassSpecWavelet’s threshold for SNR
was kept constant while amplitude was varied to identify different number of peaks.
Rows 4 to 6 present results where SNR was varied and amplitude was slightly tuned
so as to obtain an equivalent of 195 peaks to match that obtained by our algorithm.
As can be seen, our algorithm provides better sensitivity for all cases.

4.4.2

Peak Alignment

Results of peak alignment across samples were visually validated on the PF2D
chromatograms. Sample alignment is explained in Figure 4.16 and a larger section of
the alignment is presented in Figure 4.17. As explained in Figure 4.16, the objective
of the optimization model was to align peaks in Sample 2 against peaks in Sample
1. The dark blue lines indicate the original location of the identified peaks (using
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Table 4.1. Sensitivity of detection of known peaks in the Aurum data
Our Algorithm
Number of Identified Peaks
Sensitivity (%)
155

82.7

209

84.6

305

90.4

195

81.8

195

81.8

195

81.8

MassSpecWavelet
Number of Identified Peaks
Sensitivity (%)
(Thresholds: SNR, Amplitude)
151
65.4
(1, 0.01)
210
69.2
(1, 0.0075)
305
75.0
(1, 0.0049)
197
67.3
(3, 0.007)
201
67.3
(2, 0.007)
195
67.3
(1, 0.0075)

Figure 4.16. Peak alignment on PF2D data was visually validated
L from Section 4.3.1), and the light blue lines indicate the shifted location (output
from the optimization model in Section 4.3.2). Notice that, from the example shown
in the Figure, visually speaking we can say that peaks A and B represent the same
protein, hence confirming the results from the optimization model (where the light
blue line corresponds to crest of peak B indicating that peak A has been aligned with
peak B). Similar visual confirmation of alignments was conducted on several sections
of multiple datasets.
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Figure 4.17. A portion of PF2D chromatograms illustrating peak alignments
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